A Phase 2 interventional study of NNC0114-0006 and liraglutide in Diabetes and Diabetes Mellitus, Type 1, sponsored by Novo Nordisk A/S. Completed at 108 sites in 18 countries. Open to participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2021-04-09.
Sponsored by Novo Nordisk A/S · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies testing liraglutide in Diabetes Mellitus, Type 1 — 2 open to participants now, 2 under way, none of them phase 3. Liraglutide · Diabetes Mellitus, Type 1.
Among the 32 studies testing liraglutide in Diabetes Mellitus, Type 1, this one is the 3rd largest by enrollment, is one of 6 that started in 2015, is one of 10 in phase 2, and was the 19th registered.
3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →2 of the 32 studies testing liraglutide in Diabetes Mellitus, Type 1 are open now, in 2 countries. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 25–70
Second Xiangya Hospital of Central South University · Sites in China
Ages 18+
By country, each count listing its studies:
Liraglutide: first FDA approval 2010 (VICTOZA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 412 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 258 (63%) stop at 75 or younger; 185 take children under 18; 64 take healthy volunteers.
This study: 18 Years to 45 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 14 · Phase 3 12 · Phase 4 3
First in 2012; this study’s year is marked. 6 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 308 is above the median of 40 across 2,820 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 38 across the 32 interventional studies. Of the 25 that completed or were terminated, 12 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 32 have an industry lead sponsor. The 10 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
226 studies in Diabetes Mellitus, Type 1 by Novo Nordisk A/S: 2 open now, 5 under way, 1 of them phase 3. Of 220 finished, 33 (15%) have results posted.
Among the 226 studies in Diabetes Mellitus, Type 1 by Novo Nordisk A/S, this one is the 35th largest by enrollment of the 149 interventional ones that give a count, is one of 9 that started in 2015, is one of 8 in phase 2, and was the 183rd registered.
Novo Nordisk A/S’s Diabetes Mellitus, Type 1 studies by the year they started, since 1989.
None of the studies under way reaches primary completion within a year.
Among the 32 studies testing liraglutide in Diabetes Mellitus, Type 1, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novo Nordisk A/S’s 226 in Diabetes Mellitus, Type 1:
This tab as a report to print or save as PDF → With an account.
This trial is conducted globally. The aim of this trial is to assess the clinical proof-of-principle of NNC0114-0006 and liraglutide on preservation of beta-cell function in adult subjects with newly diagnosed type 1 diabetes mellitus.
3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
This study's enrollment of 308 is above the median of 40 across 2,820 interventional studies indexed under Diabetes Mellitus, Type 1.
Browse Diabetes Mellitus, Type 1 studies →Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
Compared within Diabetes Mellitus, Type 1, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: NNC0114-0006 · Drug: liraglutide
Drug: NNC0114-0006 · Drug: placebo
Drug: liraglutide · Drug: placebo
Drug: placebo
NNC0114-0006 12 mg/kg administered i.v (intravenously) every 6 weeks. Subjects will continue their pre-trial insulin treatment
Liraglutide 1.8 mg administered s.c. (subcutaneously) daily. Subjects will continue their pre-trial insulin treatment
Placebo administered s.c (subcutaneously) or i.v ( intravenously). Subjects will continue their pre-trial insulin treatment
Area Under the Concentration-time Curve (AUC) 0-4h of Mixed Meal Tolerance Test (MMTT) Stimulated C-peptide at Week 54 Relative to Baseline
Area under the concentration-time curve, from 0 to 4 hours (AUC0-4h) of a mixed meal tolerance test (MMTT) stimulated C-peptide at week 54 is presented as ratio to baseline. AUC of C-peptide was measured as Nano moles\*hour per liter (nmol\*h/L).
Time frame: 0 - 4 hours post-dose on week 0 and week 54
AUC0-2h of C-peptide at Week 54 Relative to Baseline
Area under the concentration-time curve, from 0 to 2 hours (AUC0-2h) of a MMTT stimulated C-peptide at week 54 is presented as ratio to baseline. AUC of C-peptide was measured as 'nmol\*h/L'.
Time frame: 0-2 hours post-dose on week 0 and week 54
Cmax of C-peptide at Week 54 Relative to Baseline
Maximum observed concentration (Cmax) of a MMTT stimulated C-peptide at week 54 is presented as ratio to baseline. Cmax of C-peptide was measured as nanomoles per liter (nmol/L).
Time frame: 0-4 hours post-dose on week 0 and week 54
AUC0-4h of Glucose at Week 54 Relative to Baseline
Area under the concentration-time curve, from 0 to 4 hours (AUC0-4h) of a MMTT stimulated glucose at week 54 is presented as ratio to baseline. AUC of glucose was measured as Milli moles\*hour per liter (mmol\*h/L).
Time frame: 0 - 4 hours post-dose on week 0 and week 54
AUC0-2h of Glucose at Week 54 Relative to Baseline
Area under the concentration-time curve, from 0 to 2 hours (AUC0-2h) of a MMTT stimulated glucose at week 54 is presented as ratio to baseline. AUC of glucose is measured as 'mmol\*h/L'.
Time frame: 0-2 hours post-dose on week 0 and week 54
Cmax of Glucose at Week 54 Relative to Baseline
Maximum observed concentration (Cmax) of a MMTT stimulated glucose at week 54 is presented as ratio to baseline. Cmax of C-peptide was measured as 'mmol/L'.
Time frame: 0-4 hours post-dose on week 0 and week 54
Number of Treatment Emergent Adverse Events
An adverse event was any untoward medical occurrence in a participants administered a product, and which did not necessarily have a causal relationship with this treatment. An adverse event was defined as treatment emergent if the onset of the adverse event occurs on or after the first day of trial product administration. Number of treatment emergent adverse events from first dose of trial product to week 54 and week 80 are presented. Results are based on the on-treatment and on-observation period. On-treatment period: From the day of first trial product administration to the day of the visit at week 54. On-observation: From the day after the visit at week 54 to the day of the last visit.
Time frame: Week 0-54; Week 54-80
Number of Treatment Emergent Hyperglycaemic Episodes
Hyperglycaemic episodes were defined as treatment-emergent if the onset occurred on or after the first day of trial product administration. Number of treatment emergent episodes of hyperglycaemic episodes from first dose of trial product to week 54 and from week 54 to week 80 are presented. Results are based on the on-treatment and on-observation period. On-treatment period: From the day of first trial product administration to the day of the visit at week 54. On-observation: From the day after the visit at week 54 to the day of the last visit.
Time frame: Week 0-54; Week 54-80
Number of Treatment Emergent Episodes of Diabetic Ketoacidosis
Diabetic ketoacidosis episodes were defined as treatment-emergent if the onset occurred on or after the first day of trial product administration. Number of treatment emergent episodes of hyperglycaemic episodes from first dose of trial product to week 54 and from week 54 to week 80 are presented. Results are based on the on-treatment and on-observation period. On-treatment period: From the day of first trial product administration to the day of the visit at week 54. On-observation: From the day after the visit at week 54 to the day of the last visit.
Time frame: Weeks 0-54; Weeks 54-80
Number of Participants Experiencing Treatment Emergent Injection/Infusion Site Reactions Caused by NNC0114-0006/Liraglutide/Placebo Injection/Infusion
Injection/infusion site reactions episodes were defined as treatment-emergent if the onset occurred on or after the first day of trial product administration. Number of participants experiencing treatment emergent episodes of injection/infusion site reactions episodes from first dose of trial product to week 54 (treatment period) is presented.
Time frame: Week 0-54
Number of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association (ADA)
Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 1 day after the date of last contact. Number of treatment-emergent hypoglycaemic episodes according to American Diabetes Association (ADA) classification from first dose of trial product to week 54 and from week 54 to week 80 are presented. Results presented hypoglycaemia episodes were recorded as per ADA definition: Severe hypoglycaemia, Documented symptomatic hypoglycaemia, Asymptomatic hypoglycaemia, Probable symptomatic hypoglycaemia and Pseudo-hypoglycaemia.
Time frame: Weeks 0-54; Weeks 54-80
Number of Treatment Emergent Hypoglycaemic Episodes According to Novo Nordisk Definitions
Hypoglycaemia episodes were recorded as per Novo Nordisk definition: Symptomatic BG-confirmed: An episode that is blood glucose (BG) confirmed by plasma glucose (PG) value \<3.1 mmol/L with symptoms consistent with hypoglycaemia. Asymptomatic BG-confirmed: An episode that is BG-confirmed by PG value \<3.1 mmol/L without symptoms consistent with hypoglycaemia. Severe or BG-confirmed symptomatic: An episode that is severe according to the ISPAD classification or BG-confirmed by a PG value \<3.1 mmol/L with symptoms consistent with hypoglycaemia. BG-confirmed: An episode that is BG-confirmed by a PG value \<3.1 mmol/L with or without symptoms consistent with hypoglycaemia. Severe or BG-confirmed: An episode that is severe according to the International Society for Pediatric and Adolescent Diabetes (ISPAD) classification or BG-confirmed by a PG value \<3.1 mmol/L with or without symptoms consistent with hypoglycaemia.
Time frame: Weeks 0-54; Weeks 54-80
Change in Body Weight (kg)
Change in body weight is measured at week 54 and week 80 respective to baseline. Body weight was measured in unit 'Kg'.
Time frame: (Week 0, week 54) and (week 0, week 80)
Diabetes Retinopathy
Number of participants evaluated for diabetic retinopathy at baseline (Day -28 to -14), week 54 and week 80 are presented as 'yes', 'no' or 'unknown'.
Time frame: Baseline, week 54 and week 80
Estimated Glomerular Filtration Rate (eGFR)- Ratio to Baseline
The eGFR was measured using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula. Change in eGFR (measured in milliliters per minute per 1.73 square meters) from baseline (week 0) at week 54 and week 80 is presented as ratio to baseline.
Time frame: (Week 0, week 54) and (week 0, week 80)
Change in Haematology: Erythrocytes
Change in erythrocytes (measured in 10\^12 cells per liter) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.
Time frame: (Week 0, week 54) and (week 0, week 80)
Change in Haematology: Haematocrit
Change in haematocrit (measured in percentage '%') from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.
Time frame: (Week 0, week 54) and (week 0, week 80)
Change in Haematology: Haemoglobin
Change in haemoglobin (measured in millimoles per liter 'mmol/L') from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.
Time frame: (Week 0, week 54) and (week 0, week 80)
Change in Haematology: Leukocytes
Change in leukocytes (measured in 10\^9 cells/L) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.
Time frame: (Week 0, week 54) and (week 0, week 80)
Change in Haematology: Mean Corpuscular Hemoglobin
Change in mean Corpuscular hemoglobin (measured in femtomole 'fmol') from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.
Time frame: (Week 0, week 54) and (week 0, week 80)
Change in Haematology: Mean Corpuscular Hemoglobin Concentration
Change in mean corpuscular hemoglobin concentration (MCHC) (measured in gram per liter 'g/L') from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.
Time frame: (Week 0, week 54) and (week 0, week 80)
Change in Haematology: Mean Corpuscular Volume
Change in Mean Corpuscular volume (measured in femtoliter 'fL') from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.
Time frame: (Week 0, week 54) and (week 0, week 80)
Change in Haematology: Thrombocytes
Change in thrombocytes (measured in 10\^9 cells per liter) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.
Time frame: (Week 0, week 54) and (week 0, week 80)
Change in Haematology: Eosinophil
Change in eosinophil (measured in percentage '%') from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.
Time frame: (Week 0, week 54) and (week 0, week 80)
Change in Haematology: Neutrophils
Change in neutrophils (measured in percentage '%') from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.
Time frame: (Week 0, week 54) and (week 0, week 80)
Change in Haematology: Basophils
Change in basophils (measured in percentage '%') from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.
Time frame: (Week 0, week 54) and (week 0, week 80)
Change in Haematology: Lymphocytes
Change in lymphocytes (measured in percentage '%') from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.
Time frame: (Week 0, week 54) and (week 0, week 80)
Change in Haematology: Monocytes
Change in monocytes (measured in percentage '%') from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.
Time frame: (Week 0, week 54) and (week 0, week 80)
Change in Biochemistry: Alanine Aminotransferase (ALAT)
Change in ALAT (measured in units per liter \[U/L\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.
Time frame: (Week 0, week 54) and (week 0, week 80)
Change in Biochemistry: Albumin
Change in albumin (measured in gram per deciliter \[g/dL\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.
Time frame: (Week 0, week 54) and (week 0, week 80)
Change in Biochemistry: Amylase
Change in amylase (measured in units per liter \[U/L\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.
Time frame: (Week 0, week 54) and (week 0, week 80)
Change in Biochemistry: Alkaline Phosphatase (ALP)
Change in ALP (measured in units per liter \[U/L\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.
Time frame: (Week 0, week 54) and (week 0, week 80)
Change in Biochemistry: Aspartate Aminotransferase (ASAT)
Change in ASAT (measured in units per liter \[U/L\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.
Time frame: (Week 0, week 54) and (week 0, week 80)
Change in Biochemistry: Total Bilirubin
Change in Total bilirubin (measured in micromole per liter \[umol/L\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.
Time frame: (Week 0, week 54) and (week 0, week 80)
Change in Biochemistry: Calcium Corrected
Change in calcium corrected (measured in millimole per liter \[mmol/L\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.
Time frame: (Week 0, week 54) and (week 0, week 80)
Change in Biochemistry: Chloride
Change in chloride (measured in millimole per liter \[mmol/L\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.
Time frame: (Week 0, week 54) and (week 0, week 80)
Change in Biochemistry: Creatine Kinase
Change in creatine kinase (measured in units per liter \[U/L\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.
Time frame: (Week 0, week 54) and (week 0, week 80)
Change in Biochemistry: Creatinine
Change in creatinine (measured in micromole per liter \[umol/L\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.
Time frame: (Week 0, week 54) and (week 0, week 80)
Change in Biochemistry: Gamma-glutamyl Transferase (GGT)
Change in GGT (measured in units per liter \[U/L\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.
Time frame: (Week 0, week 54) and (week 0, week 80)
Change in Biochemistry: C-reactive Protein Serum
Change in C-reactive protein serum (measured in milligrams per liter \[mg/L\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.
Time frame: (Week 0, week 54) and (week 0, week 80)
Change in Biochemistry: Lactate Dehydrogenase
Change in Lactate Dehydrogenase (measured in units per liter \[U/L\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.
Time frame: (Week 0, week 54) and (week 0, week 80)
Change in Biochemistry: Lipase
Change in lipase (measured in units per liter \[U/L\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.
Time frame: (Week 0, week 54) and (week 0, week 80)
Change in Biochemistry: Magnesium
Change in magnesium (measured in millimole per liter \[mmol/L\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.
Time frame: (Week 0, week 54) and (week 0, week 80)
Change in Biochemistry: Phosphate
Change in phosphate (measured in millimole per liter \[mmol/L\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.
Time frame: (Week 0, week 54) and (week 0, week 80)
Change in Biochemistry: Potassium
Change in potassium (measured in millimole per liter \[mmol/L\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.
Time frame: (Week 0, week 54) and (week 0, week 80)
Change in Biochemistry: Sodium
Change in sodium (measured in millimole per liter \[mmol/L\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.
Time frame: (Week 0, week 54) and (week 0, week 80)
Change in Biochemistry: Total Protein
Change in total protein (measured in gram per liter \[g/dL\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.
Time frame: (Week 0, week 54) and (week 0, week 80)
Change in Biochemistry: Blood Urea Nitrogen Serum
Change in blood urea nitrogen serum (measured in milligram per deciliter \[mg/dL\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.
Time frame: (Week 0, week 54) and (week 0, week 80)
Change in Biochemistry: Uric Acid
Change in Uric Acid (measured in milligram per deciliter \[mg/dL\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.
Time frame: (Week 0, week 54) and (week 0, week 80)
Change in International Normalised Ratio (INR)
Change in INR (measured in ratio\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.
Time frame: (Week 0, week 54) and (week 0, week 80)
Change in D-Dimer
Change in D-Dimer (measured in mg/L) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.
Time frame: (Week 0, week 54) and (week 0, week 80)
Change in Lipids: Total Cholesterol (Ratio to Baseline)
Change in total cholesterol (measured in mmol/L) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.
Time frame: (Week 0, week 54) and (week 0, week 80)
Change in Lipids: Free Fatty Acids (Ratio to Baseline)
Change in total free fatty acids (measured in mmol/L) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.
Time frame: (Week 0, week 54) and (week 0, week 80)
Change in Lipids: HDL Cholesterol (Ratio to Baseline)
Change in HDL cholesterol (measured in mmol/L) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.
Time frame: (Week 0, week 54) and (week 0, week 80)
Change in Lipids: LDL Cholesterol (Ratio to Baseline)
Change in LDL cholesterol (measured in mmol/L) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.
Time frame: (Week 0, week 54) and (week 0, week 80)
Change in Lipids: Triglycerides (TG) (Ratio to Baseline)
Change in Triglycerides (measured in mmol/L) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.
Time frame: (Week 0, week 54) and (week 0, week 80)
Change in Total Immunoglobulin E (IgE)
Change in IgE (measured in kilo international units per liter \[kIU/L\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.
Time frame: (Week 0, week 54) and (week 0, week 80)
Change in Urinalysis: Urine Dipsticks
Urinalysis was performed by urine dipsticks for protein, glucose, erythrocytes, ketones leukocytes, nitrite, pH and specific gravity and categorised as normal, abnormal not clinically significant (NCS) and abnormal clinially significant (CS). Number of participants in each category at baseline (week 0), week 54 and 80 are presented.
Time frame: Week 0, week 54 and week 80
Change in Cytokines: Interleukin (IL)-6
IL-6 levels at baseline (week 0), weeks 54 and 80 are evaluated and presented.
Time frame: Week 0, week 54 and week 80
Change in Cytokines- Interleukin (IL)-10
IL-10 levels at baseline (week 0), weeks 54 and 80 are evaluated and presented.
Time frame: Week 0, week 54 and week 80
Change in Cytokines: Interleukin (IL)-17
IL-17 levels at baseline (week 0), weeks 54 and 80 are evaluated and presented.
Time frame: Week 0, week 54 and week 80
Change in Cytokines: Interferon (IFN) Gamma
IFN gamma levels at baseline (week 0), weeks 54 and 80 are evaluated and presented.
Time frame: Week 0, week 54 and week 80
Change in Cytokines: TNF-alpha
TNF-alpha levels at baseline (week 0), weeks 54 and 80 are evaluated and presented.
Time frame: Week 0, week 54 and week 80
Change in Hormone Level: Thyroid Stimulating Hormone (TSH)
Change in TSH (measured in milli international units per liter \[mIU/L\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.
Time frame: (Week 0, week 54) and (week 0, week 80)
Change in Hormone Level: Calcitonin
Change in Calcitonin (measured in nanogram per liter \[ng/L\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.
Time frame: (Week 0, week 54) and (week 0, week 80)
Change in Systolic and Diastolic Blood Pressure
Change in systolic blood pressure (SBP) and diastolic blood pressure (DBP) are evaluated from baseline (week 0) to weeks 54 and 80.
Time frame: (Week 0, week 54) and (week 0, week 80)
Change in Pulse
Change in pulse is evaluated from baseline (week 0) to weeks 54 and 80
Time frame: (Week 0, week 54) and (week 0, week 80)
Change in Body Temperature
Change in body temperature is evaluated from baseline (week 0) to weeks 54 and 80.
Time frame: Week 0, week 54) and (week 0, week 80)
Change in Respiratory Rate
Change in respiratory rate is evaluated from baseline (week 0) to weeks 54 and 80.
Time frame: (Week 0, week 54) and (week 0, week 80)
Change in Electrocardiogram (ECG)
The ECG was assessed by the investigator at baseline (week 0), week 54 and week 80 and categorised as normal, abnormal NCS or abnormal CS. Number of participants in each ECG category at baseline, week 54 and week 80 are presented.
Time frame: Week 0, week 54 and week 80
Change in Eye-examination
Dilated fundoscopy or fundus photography was performed by the investigator at week 0, week 54 and week 80. The results of the examination were interpreted for each eye (left/right) are categorised as normal, abnormal NCS or abnormal CS. Number of participants in each category at week 0, week 54 and week 80 are presented.
Time frame: Week 0, week 54 and week 80
Change in Physical Examination
Physical examination parameters are categorised as general appearance; head, ears, eyes, nose, throat, neck; respiratory system;cardiovascular system; gastrointestinal system including mouth; musculoskeletal system; central and peripheral nervous system; skin; lymph node palpation and thyroid gland. Investigator assessed the participants with normal, abnormal not clinically significant (NCS) and abnormal clinically significant (CS) findings at week 0, week 54 and week 80 are presented.
Time frame: Week 0, week 54 and week 80
Occurrence of Anti-NNC0114-0006 Antibodies
This outcome measure was applicable for NNC0114-0006 + Liraglutide treatment arm and NNC0114-0006 treatment arm. Participants was assessed for anti-NNC0114-0006 antibodies. Participant who reported anti-NNC0114-0006 antibodies were further analyzed for cross-reactivity. Number of participants who measured with anti-NNC0114-0006 antibodies at week 54 and week 80 are presented.
Time frame: Week 0, week 54 and week 80
Occurrence of Anti-liraglutide Antibodies
This outcome measure is applicable for NNC0114-0006 + Liraglutide treatment arm and Liraglutide treatment arm. Participants was assessed for anti-liraglutide antibodies. Participant who reported anti-liraglutide antibodies were further analyzed for cross-reactivity. Number of participants who measured with anti-liraglutide antibodies at week 54 and week 80 are presented.
Time frame: Week 0, week 54 and week 80
Change in Insulin Dose
The total daily insulin dose was derived as the average of the doses reported on the three days prior to the visit. Change in daily total insulin dose from baseline (week 0) after 54 weeks of treatment and week 80 are presented.
Time frame: (Week 0, week 54) and (week 0, week 80)
Change in Number of Insulin Injections
The number of insulin injections was derived as the average of the reported number on the three days prior to the visit. The change in number of insulin injections per day (count) from baseline (week 0) after 54 weeks of treatment and week 80 are presented.
Time frame: (Week 0, week 54) and (week 0, week 80)
Number of Weeks Off Bolus Insulin
The number of weeks off bolus insulin after 54 weeks of treatment and week 80 are presented.
Time frame: (Week 0 to week 54) and (week 0 to week 80)
Change in HbA1c
Change in glycosylated haemoglobin (HbA1c) is evaluated from baseline (week 0) to weeks 54 and 80.
Time frame: (Week 0, week 54) and (week 0, week 80)
Change in Fasting Plasma Glucose
Change in fasting plasma glucose is evaluated from baseline (week 0) to weeks 54 and 80.
Time frame: (Week 0, week 54) and (week 0, week 80)
Change in Fasting C-peptide- Ratio to Baseline
Change in fasting C-peptide (measured in nanomole per liter \[nmol/L\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.
Time frame: (Week 0, week 54) and (week 0, week 80)
Change in Fasting Glucagon- Ratio to Baseline
Change in fasting glucagon (measured in picogram per milliliter \[pg/mL\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.
Time frame: (Week 0, week 54) and (week 0, week 80)
7-point SMPG Profiles
Participants measured plasma glucose values using the blood glucose meter at 7 time points: before breakfast, 90 minutes after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 minutes after start of dinner, bedtime. 7-point SMPG profile values are presented for week 54 and week 80.
Time frame: Week 54 and Week 80
Change in 7- Points Self-measured Plasma Glucose (SMPG) Postprandial Glucose /Prandial Increment: Breakfast, Lunch, Dinner
Participants measured plasma glucose values using the blood glucose meter at 7 time points: before breakfast, 90 minutes after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 minutes after start of dinner and at bedtime. Change from baseline (week 0) to week 54 and week 80 in 7-point SMPG postprandial glucose /prandial increment (breakfast, lunch and dinner) value are presented.
Time frame: (Week 0, week 54) and (week 0, week 80)
Change in 7- Points Self-measured Plasma Glucose (SMPG) Postprandial Glucose /Prandial Increment (Average Over the Three Meals)
Participants measured plasma glucose values using the blood glucose meter at 7 time points: before breakfast, 90 minutes after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 minutes after start of dinner, bedtime. Change from baseline (week 0) to week 54 and week 80 in 7-point self-measured plasma glucose (SMPG) postprandial glucose /prandial increment (average over the three meals) value is presented.
Time frame: (Week 0, week 54) and (week 0, week 80)
Change in Mean of 7-point Profiles
Participants measured plasma glucose values using the blood glucose meter at 7 time points: before breakfast, 90 minutes after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 minutes after start of dinner, bedtime. Change from baseline (week 0) to week 54 and week 80 in mean of 7-point profiles value is presented.
Time frame: (Week 0, week 54) and (week 0, week 80)
Before Breakfast 7- Points Self Measured Plasma Glucose (SMPG)
Participants measured plasma glucose values using the blood glucose meter at 7 time points: before breakfast, 90 minutes after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 minutes after start of dinner and at bedtime. Before breakfast 7-point self-measured plasma glucose (SMPG) profile values are presented at week 54 and week 80.
Time frame: Week 54 and week 80
Area Under the NNC0114-0006 Concentration-time Curve Over a Dosing Interval at Steady State (AUCtau, NNC0114-0006)
AUCtau, NNC0114-0006 was derived as the area under the concentration-time curve using the linear trapezoidal technique based on observed values and actual measurement times between 0 and 6 weeks (after the last dose). This outcome measure was applicable for NNC0114-0006 + Liraglutide and NNC0114-0006 treatment arms.
Time frame: Pre-dose and 1 hour post-dose during week 48 to week 54
Terminal Half-life (t½) After Last Dose of NNC0114-0006
Terminal half life was calculated as log(2)/λz. The terminal rate constant λz was determined through linear regression with the logarithm to concentration as the response variable and actual measurement time as the explanatory variable. Valid observations from the terminal part of the curve, which is approximately linear, were used for the determination. This outcome measure was applicable for NNC0114-0006 + Liraglutide and NNC0114-0006 treatment arms.
Time frame: Pre-dose and 1 hour post-dose during week 48 to week 80
Apparent Volume of Distribution of NNC0114-0006 at Steadystate (Vss, NNC0114-0006)
The apparent volume of distribution of NNC0114-0006 at steady-state was calculated as mean residence time of (MRT) of NNC0114-0006 multiplied by clearance of NNC0114-0006 at steady state. This outcome measure was applicable for NNC0114-0006 + Liraglutide and NNC0114-0006 treatment arms.
Time frame: Pre-dose and 1 hour post-dose during week 48 to week 80
Clearance of NNC0114-0006 at Steady State (CLss, NNC0114-0006)
Clearance of NNC0114-0006 at steady state was calculated as dose/AUCtau, NNC0114-0006. This outcome measure was applicable for NNC0114-0006 + Liraglutide and NNC0114-0006 treatment arms.
Time frame: Pre-dose and 1 hour post-dose during week 48 to week 54
Mean Residence Time of NNC0114-0006 (MRT, NNC0114-0006)
This outcome measure was applicable for NNC0114-0006 + Liraglutide and NNC0114-0006 treatment arms. Mean residence time of NNC0114-0006 is presented.
Time frame: Pre-dose and 1 hour post-dose during week 48 to week 80
Accumulation Ratio of NNC114-0006 (RA,AUC, NNC0114-0006)
Accumulation ratio of NNC114-0006 was defined as AUC48-54 weeks/AUC0-6 weeks. This outcome measure was applicable for NNC0114-0006 + Liraglutide and NNC0114-0006 treatment arms.
Time frame: Pre-dose and 1 hour post-dose during (week 0 to week 6) and (week 48 to week 54)
Observed NNC0114-0006 Concentration Prior to Dosing of NNC0114-0006 at Steady State (Ctrough, NNC0114-0006)
Ctrough of NNC0114-0006 was defined as concentration prior to dosing of NNC0114-0006 at steady state. This outcome measure was applicable for NNC0114-0006 + Liraglutide and NNC0114-0006 treatment arms.
Time frame: Week 48 (predose)
Observed NNC0114-0006 Concentration 1 Hour After Dosing of NNC0114-0006 at Steady State (C1h, NNC0114-0006)
C1h, NNC0114-0006 was defined as concentration of NNC0114-0006 at 1 hour after dosing of NNC0114-0006 at steady state. This outcome measure was applicable for NNC0114-0006 + Liraglutide and NNC0114-0006 treatment arms.
Time frame: Week 48 (1 hour post-dose)
Liraglutide Concentration at Steady State (C Liraglutide)
C liraglutide was defined as the liraglutide concentration at steady state. This outcome measure was applicable for NNC0114-0006 + Liraglutide and Liraglutide treatment arms.
Time frame: Week 54 (post-dose)
Change in Biomarker: Immune Phenotyping- B Cell Panel
B cell panel is evaluated by Immune phenotyping of peripheral blood mononuclear cells (PBMC) at baseline (week 0), week 54 and week 80. In below table CD refer to Cluster of Differentiation; IgMNeg refers to Immunoglobulin M negative; IgDNeg refers to Immunoglobulin D negative.
Time frame: Week 0, week 54 and week 80
Change in Biomarker: Immune Phenotyping- Natural Killer (NK) Cell Panel
NK cell panel is evaluated by Immune phenotyping of peripheral blood mononuclear cells (PBMC) at baseline (week 0), week 54 and week 80. In below table ADCC refer to Antibody-dependent cellular cytotoxicity; CD refer to Cluster of Differentiation.
Time frame: Week 0, week 54 and week 80
Change in Biomarker: Immune Phenotyping- T Cell Panel
T cell panel is evaluated by Immune phenotyping of peripheral blood mononuclear cells (PBMC) at baseline (week 0), week 54 and week 80. In below table CD refer to Cluster of Differentiation; TEMRA refers to terminally differentiated effector memory cells re-expressing CD45RA; CCR refers to C-C chemokine receptor; TREG refers to Regulatory T cells.
Time frame: Week 0, week 54 and week 80
Change in Biomarker: Immune Phenotyping- T Follicular Helper (TfH) Cell Panel
TfH cell panel is evaluated by Immune phenotyping of peripheral blood mononuclear cells (PBMC) at baseline (week 0), week 54 and week 80. In below table CTFH refer to Circulating T follicular helper; ICOS refers to inducible T-cell co-stimulator; PD refers to Programmed cell death protein; CCR refers to C-C chemokine receptor; CXCR refers to C-X-C chemokine receptor; CD refer to Cluster of Differentiation; CM refers to central memory; EM refers to effector memory, TIGIT refers to T cell immunoreceptor with Ig and ITIM domains.
Time frame: Week 0, week 54 and week 80
Change in Biomarker: Immune Phenotyping- Myeloid Cell Panel
Myeloid panel is evaluated by Immune phenotyping of peripheral blood mononuclear cells (PBMC) at baseline (week 0), week 54 and week 80. In below table HLA refers to Human Leukocyte Antigen; MDSC refers to myeloid-derived suppressor cell; DC refers to Dendritic cells; MYDC refers to Myeloid Dendritic Cells; IMMYE_MDSC refers to Immature myeloid cells \& a subset of myeloid suppressor cells within the CD14-HLA class II- myeloid cell population.
Time frame: Week 0, week 54 and week 80
Autoantibodies Against Glutamic Acid Decarboxylase (GAD)
Participants were analyzed for autoantibodies against Glutamic acid decarboxylase (GAD) and were categorized as negative and positive.
Time frame: Week 0, week 54 and week 80
Autoantibodies Against Zinc-transporter 8 (ZnT8)
Participants were analyzed for autoantibodies against Zinc-transporter 8 (ZnT8) and were categorized as negative and positive.
Time frame: Week 0, week 54 and week 80
Autoantibodies Against Islet Antigen-2 (IA2)
Participants were analyzed for autoantibodies against Islet antigen-2 (IA2) and were categorized as negative and positive.
Time frame: Week 0, week 54 and week 80
Autoantibodies Against Insulin Autoantibodies (IAA)
Participants were analyzed for autoantibodies against Insulin autoantibodies (IAA) and were categorized as negative and positive.
Time frame: Week 0, week 54 and week 80
Change in Biomarker: Total Interleukin-21 (IL-21)
IL-21 is evaluated at baseline (week 0), week 54 and week 80.
Time frame: Week 0, week 54 and week 80
Change in Biomarker: Serum Vitamin D (1,25 Dehydroxy-calciferol)
Serum vitamin D is evaluated at baseline (week 0), week 54 and week 80.
Time frame: Week 0, week 54 and week 80
Change in Short Form 36 Health Survey (SF-36)
SF-36v2™ questionnaire measured the HRQoL on 8 domains (Bodily Pain, General Health, Mental Health, Physical Functioning, Role Emotion, Physical Health, Social Functioning and Vitality) on individual scale ranges. The scores 0-100 (where higher scores indicated a better HRQoL) from the SF-36 were converted to norm-based scores to enable a direct interpretation in relation to the distribution of the scores in the 2009 U.S. general population. Change from baseline (week 0) to week 54 and week 80 in SF-36 score is presented.The MCS measure is derived from domain scales of vitality, social functioning, role emotional and mental health. The PCS measure is derived from domain scales of physical functioning, role-physical, bodily pain, and general health. A norm-based score of 50 corresponds to the mean score and 10 corresponds to the standard deviation of the 2009 U.S. general population. A positive change score indicate an improvement since baseline.
Time frame: (Week 0, week 54) and (week 0, week 80)
Change in Experience of Treatment Benefits and Barriers (ETBB)
Treatment Benefits and Barriers (ETBB) questionnaire measured diabetes-specific health beliefs on 2 categories: Total Score for Perceived Barriers and Perceived Benefits. The measurement of perceived benefits of, and barriers to, treatment was achieved by creating a pool 28 statements each with a 7-point scale ranging from strongly agree (6) to strongly disagree (0). ETBB benefits score was calculated using the responses from questions 1, 4, 7, 8, 10, and 12 and ETBB barriers score was calculated using the responses from questions 2, 3, 5, 6, 9, and 11. Both was calculated as the sum of responses divided by number of responses received multiplied by the maximum number of responses. Based on the responses used the maximum responses available was 6. The higher score indicates more perceived benefits or more perceived barrier.
Time frame: (Week 0, week 54) and (week 0, week 80)
Change in Diabetes Treatment Satisfaction Questionnaire (DTSQ)
Change from baseline (week 0) in DTSQ is evaluated at week 54 and 80. The DTSQs items are scored on a 7-point graded response scale ranging from 6 to 0. Higher score indicates a higher level of glycaemia/treatment satisfaction.
Time frame: (Week 0, week 54) and (week 0, week 80)
Area Under the Concentration-time Curve (AUC) 0-4h of Mixed Meal Tolerance Test (MMTT) Stimulated C-peptide at Week 80 Relative to Baseline
Area under the concentration-time curve, from 0 to 4 hours (AUC0-4h) of a mixed meal tolerance test (MMTT) stimulated C-peptide at week 80 is presented as ratio to baseline. AUC of C-peptide was measured as Nano moles\*hour per liter (nmol\*h/L).
Time frame: 0 - 4 hours post-dose on week 0 and week 80
AUC0-2h of C-peptide at Week 80 Relative to Baseline
Area under the concentration-time curve, from 0 to 2 hours (AUC0-2h) of a MMTT stimulated C-peptide at week 80 is presented as ratio to baseline. AUC of C-peptide was measured as 'nmol\*h/L'.
Time frame: 0-2 hours post-dose on week 0 and week 80
Cmax of C-peptide at Week 80 Relative to Baseline
Maximum observed concentration (Cmax) of a MMTT stimulated C-peptide at week 80 is presented as ratio to baseline. Cmax of C-peptide was measured as nanomoles per liter (nmol/L).
Time frame: 0-4 hours post-dose on week 0 and week 80
AUC0-4h of Glucose at Week 80 Relative to Baseline
Area under the concentration-time curve, from 0 to 4 hours (AUC0-4h) of a MMTT stimulated glucose at week 80 is presented as ratio to baseline. AUC of glucose was measured as Milli moles\*hour per liter (mmol\*h/L).
Time frame: 0 - 4 hours post-dose on week 0 and week 80
AUC0-2h of Glucose at Week 80 Relative to Baseline
Area under the concentration-time curve, from 0 to 2 hours (AUC0-2h) of a MMTT stimulated glucose at week 80 is presented as ratio to baseline. AUC of glucose was measured as 'mmol\*h/L'.
Time frame: 0-2 hours post-dose on week 0 and week 80
Cmax of Glucose at Week 80 Relative to Baseline
Maximum observed concentration (Cmax) of a MMTT stimulated glucose at week 80 is presented as ratio to baseline. Cmax of C-peptide was measured as 'mmol/L'.
Time frame: 0-4 hours post-dose on week 0 and week 80
The trial was conducted at 94 sites in Austria, Belgium, Canada, Denmark, Finland, Ireland, Israel, Italy, Norway, Poland, Portugal, Russian Federation, Spain, Sweden, Ukraine, the United Kingdom (UK), and the United States (US).
| Milestone | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Started | 77 | 77 | 76 | 77 |
| Full analysis set | 77 | 77 | 76 | 77 |
| Pk analysis set | 21 | 21 | 22 | 20 |
| Safety analysis set | 77 | 77 | 76 | 77 |
| Completed | 65 | 63 | 67 | 61 |
| Not completed | 12 | 14 | 9 | 16 |
| Withdrew: Adverse event | 3 | 4 | 1 | 2 |
| Withdrew: Unclassified | 0 | 0 | 2 | 1 |
| Withdrew: Withdrawal by subject | 4 | 7 | 3 | 9 |
| Withdrew: Pregnancy | 3 | 1 | 1 | 2 |
| Withdrew: Lost to follow-up | 1 | 2 | 0 | 1 |
| Withdrew: Protocol violation | 1 | 0 | 1 | 1 |
| Withdrew: Death | 0 | 0 | 1 | 0 |
Area under the concentration-time curve, from 0 to 4 hours (AUC0-4h) of a mixed meal tolerance test (MMTT) stimulated C-peptide at week 54 is presented as ratio to baseline. AUC of C-peptide was measured as Nano moles\*hour per liter (nmol\*h/L).
| Ratio of AUC | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Area Under the Concentration-time Curve (AUC) 0-4h of Mixed Meal Tolerance Test (MMTT) Stimulated C-peptide at Week 54 Relative to Baseline | 0.934 ± 61.9 | 0.783 ± 45.5 | 0.709 ± 104.8 | 0.660 ± 86.3 |
Area under the concentration-time curve, from 0 to 2 hours (AUC0-2h) of a MMTT stimulated C-peptide at week 54 is presented as ratio to baseline. AUC of C-peptide was measured as 'nmol\*h/L'.
| Ratio of AUC | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| AUC0-2h of C-peptide at Week 54 Relative to Baseline | 0.961 ± 65.4 | 0.824 ± 53.0 | 0.646 ± 97.4 | 0.655 ± 87.3 |
Maximum observed concentration (Cmax) of a MMTT stimulated C-peptide at week 54 is presented as ratio to baseline. Cmax of C-peptide was measured as nanomoles per liter (nmol/L).
| Ratio of Cmax | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Cmax of C-peptide at Week 54 Relative to Baseline | 0.978 ± 70.3 | 0.779 ± 47.6 | 0.733 ± 110.4 | 0.644 ± 89.4 |
Area under the concentration-time curve, from 0 to 4 hours (AUC0-4h) of a MMTT stimulated glucose at week 54 is presented as ratio to baseline. AUC of glucose was measured as Milli moles\*hour per liter (mmol\*h/L).
| Ratio of AUC | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| AUC0-4h of Glucose at Week 54 Relative to Baseline | 0.904 ± 33.1 | 1.078 ± 31.8 | 0.993 ± 34.2 | 1.089 ± 36.7 |
Area under the concentration-time curve, from 0 to 2 hours (AUC0-2h) of a MMTT stimulated glucose at week 54 is presented as ratio to baseline. AUC of glucose is measured as 'mmol\*h/L'.
| Ratio of AUC | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| AUC0-2h of Glucose at Week 54 Relative to Baseline | 0.939 ± 28.5 | 1.066 ± 24.8 | 0.978 ± 31.9 | 1.057 ± 31.3 |
Maximum observed concentration (Cmax) of a MMTT stimulated glucose at week 54 is presented as ratio to baseline. Cmax of C-peptide was measured as 'mmol/L'.
| Ratio of Cmax | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Cmax of Glucose at Week 54 Relative to Baseline | 0.937 ± 27.8 | 1.068 ± 25.4 | 1.004 ± 29.1 | 1.057 ± 30.9 |
An adverse event was any untoward medical occurrence in a participants administered a product, and which did not necessarily have a causal relationship with this treatment. An adverse event was defined as treatment emergent if the onset of the adverse event occurs on or after the first day of trial product administration. Number of treatment emergent adverse events from first dose of trial product to week 54 and week 80 are presented. Results are based on the on-treatment and on-observation period. On-treatment period: From the day of first trial product administration to the day of the visit at week 54. On-observation: From the day after the visit at week 54 to the day of the last visit.
| Adverse events | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Week 0-54 | 434 | 327 | 410 | 364 |
| Week 54-80 | 70 | 73 | 78 | 87 |
Hyperglycaemic episodes were defined as treatment-emergent if the onset occurred on or after the first day of trial product administration. Number of treatment emergent episodes of hyperglycaemic episodes from first dose of trial product to week 54 and from week 54 to week 80 are presented. Results are based on the on-treatment and on-observation period. On-treatment period: From the day of first trial product administration to the day of the visit at week 54. On-observation: From the day after the visit at week 54 to the day of the last visit.
| Episodes | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Week 0-54 | 302 | 256 | 217 | 291 |
| Week 54-80 | 306 | 74 | 352 | 112 |
Diabetic ketoacidosis episodes were defined as treatment-emergent if the onset occurred on or after the first day of trial product administration. Number of treatment emergent episodes of hyperglycaemic episodes from first dose of trial product to week 54 and from week 54 to week 80 are presented. Results are based on the on-treatment and on-observation period. On-treatment period: From the day of first trial product administration to the day of the visit at week 54. On-observation: From the day after the visit at week 54 to the day of the last visit.
| Episodes | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Week 0-54 | 0 | 0 | 0 | 0 |
| Week 54-80 | 0 | 0 | 1 | 1 |
Injection/infusion site reactions episodes were defined as treatment-emergent if the onset occurred on or after the first day of trial product administration. Number of participants experiencing treatment emergent episodes of injection/infusion site reactions episodes from first dose of trial product to week 54 (treatment period) is presented.
| Participants | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Number of Participants Experiencing Treatment Emergent Injection/Infusion Site Reactions Caused by NNC0114-0006/Liraglutide/Placebo Injection/Infusion | 2 | 0 | 0 | 1 |
Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 1 day after the date of last contact. Number of treatment-emergent hypoglycaemic episodes according to American Diabetes Association (ADA) classification from first dose of trial product to week 54 and from week 54 to week 80 are presented. Results presented hypoglycaemia episodes were recorded as per ADA definition: Severe hypoglycaemia, Documented symptomatic hypoglycaemia, Asymptomatic hypoglycaemia, Probable symptomatic hypoglycaemia and Pseudo-hypoglycaemia.
| Episodes | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Severe hypoglycaemia (Week 0-54) | 1 | 2 | 0 | 0 |
| Asymptomatic hypoglycaemia (Week 0-54) | 2038 | 1956 | 2092 | 1774 |
| Documented symptomatic hypoglycaemia (Week 0-54) | 1305 | 1461 | 1114 | 1625 |
| Pseudo-hypoglycaemia (Week 0-54) | 1 | 1 | 14 | 2 |
| Probable symptomatic hypoglycaemia (Week 0-54) | 9 | 0 | 4 | 10 |
| Severe hypoglycaemia (Week 54-80) | 3 | 1 | 0 | 1 |
| Asymptomatic hypoglycaemia (Week 54-80) | 609 | 522 | 670 | 449 |
| Documented symptomatic hypoglycaemia (Week 54-80) | 514 | 362 | 651 | 527 |
| Pseudo-hypoglycaemia (Week 54-80) | 0 | 0 | 1 | 2 |
| Probable symptomatic hypoglycaemia (Week 54-80) | 1 | 0 | 0 | 2 |
Hypoglycaemia episodes were recorded as per Novo Nordisk definition: Symptomatic BG-confirmed: An episode that is blood glucose (BG) confirmed by plasma glucose (PG) value \<3.1 mmol/L with symptoms consistent with hypoglycaemia. Asymptomatic BG-confirmed: An episode that is BG-confirmed by PG value \<3.1 mmol/L without symptoms consistent with hypoglycaemia. Severe or BG-confirmed symptomatic: An episode that is severe according to the ISPAD classification or BG-confirmed by a PG value \<3.1 mmol/L with symptoms consistent with hypoglycaemia. BG-confirmed: An episode that is BG-confirmed by a PG value \<3.1 mmol/L with or without symptoms consistent with hypoglycaemia. Severe or BG-confirmed: An episode that is severe according to the International Society for Pediatric and Adolescent Diabetes (ISPAD) classification or BG-confirmed by a PG value \<3.1 mmol/L with or without symptoms consistent with hypoglycaemia.
| Episodes | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Severe or BG confirmed (Week 0-54) | 396 | 394 | 315 | 503 |
| Symptomatic BG confirmed (Week 0-54) | 576 | 616 | 479 | 646 |
| Severe or BG confirmed (Week 54-80) | 216 | 130 | 244 | 240 |
| Symptomatic BG confirmed (Week 54-80) | 368 | 207 | 332 | 292 |
Change in body weight is measured at week 54 and week 80 respective to baseline. Body weight was measured in unit 'Kg'.
| Kilogram (Kg) | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Change from week 0 to week 54 | -1.8 ± 4.2 | 1.2 ± 5.0 | -2.5 ± 4.0 | 1.1 ± 6.1 |
| Change from week 0 to week 80 | 1.9 ± 4.6 | 1.6 ± 5.2 | 0.4 ± 4.7 | 2.8 ± 5.5 |
Number of participants evaluated for diabetic retinopathy at baseline (Day -28 to -14), week 54 and week 80 are presented as 'yes', 'no' or 'unknown'.
| Participants | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Baseline (Day:-28 to -14) — Yes | 4 | 2 | 1 | 1 |
| Baseline (Day:-28 to -14) — No | 73 | 75 | 75 | 76 |
| Baseline (Day:-28 to -14) — Unknown | 0 | 0 | 0 | 0 |
| Week 54 — Yes | 3 | 2 | 1 | 0 |
| Week 54 — No | 65 | 63 | 68 | 68 |
| Week 54 — Unknown | 0 | 0 | 0 | 0 |
| Week 80 — Yes | 3 | 2 | 1 | 0 |
| Week 80 — No | 65 | 62 | 67 | 63 |
| Week 80 — Unknown | 1 | 1 | 1 | 1 |
The eGFR was measured using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula. Change in eGFR (measured in milliliters per minute per 1.73 square meters) from baseline (week 0) at week 54 and week 80 is presented as ratio to baseline.
| Ratio of eGFR | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Change from week 0 to week 54 | 0.98 ± 10.3 | 0.95 ± 8.2 | 0.97 ± 10.2 | 1.00 ± 8.8 |
| Change from week 0 to week 80 | 0.97 ± 9.3 | 0.94 ± 11.4 | 0.96 ± 11.5 | 0.99 ± 10.9 |
Change in erythrocytes (measured in 10\^12 cells per liter) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.
| ratio of erythrocytes | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Change from week 0 to week 54 | 0.99 ± 6.00 | 1.01 ± 6.3 | 0.99 ± 7.2 | 1.00 ± 6.0 |
| Change from week 0 to week 80 | 0.99 ± 6.7 | 1.00 ± 6.7 | 0.99 ± 7.00 | 1.00 ± 5.5 |
Change in haematocrit (measured in percentage '%') from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.
| ratio of haematocrit | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Change from week 0 to week 54 | 0.99 ± 6.6 | 1.00 ± 7.00 | 0.99 ± 7.8 | 1.00 ± 5.9 |
| Change from week 0 to week 80 | 0.98 ± 7.5 | 1.00 ± 7.3 | 0.98 ± 7.2 | 0.99 ± 5.8 |
Change in haemoglobin (measured in millimoles per liter 'mmol/L') from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.
| ratio of haemoglobin | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Change from week 0 to week 54 | 1.01 ± 6.1 | 1.02 ± 7.2 | 1.00 ± 7.9 | 1.01 ± 5.6 |
| Change from week 0 to week 80 | 1.00 ± 7.5 | 1.02 ± 8.2 | 1.00 ± 7.4 | 1.01 ± 5.6 |
Change in leukocytes (measured in 10\^9 cells/L) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.
| ratio of leukocytes | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Change from week 0 to week 54 | 0.96 ± 27.1 | 0.98 ± 21.9 | 0.97 ± 23.2 | 1.02 ± 24.8 |
| Change from week 0 to week 80 | 0.99 ± 33.0 | 0.95 ± 19.9 | 0.99 ± 29.5 | 1.00 ± 24.9 |
Change in mean Corpuscular hemoglobin (measured in femtomole 'fmol') from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.
| ratio of mean Corpuscular hemoglobin | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Change from week 0 to week 54 | 1.02 ± 3.6 | 1.01 ± 4.8 | 1.01 ± 4.0 | 1.01 ± 4.1 |
| Change from week 0 to week 80 | 1.02 ± 5.1 | 1.01 ± 6.6 | 1.01 ± 5.4 | 1.02 ± 4.3 |
Change in mean corpuscular hemoglobin concentration (MCHC) (measured in gram per liter 'g/L') from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.
| Ratio of MCHC | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Change from week 0 to week 54 | 1.02 ± 2.9 | 1.01 ± 2.1 | 1.02 ± 2.6 | 1.02 ± 3.0 |
| Change from week 0 to week 80 | 1.02 ± 3.5 | 1.02 ± 3.1 | 1.02 ± 3.0 | 1.02 ± 0.29 |
Change in Mean Corpuscular volume (measured in femtoliter 'fL') from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.
| ratio of mean corpuscular volume | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Change from week 0 to week 54 | 1.00 ± 2.8 | 0.99 ± 3.8 | 1.00 ± 3.3 | 0.99 ± 3.3 |
| Change from week 0 to week 80 | 1.00 ± 4.3 | 1.00 ± 5.2 | 1.00 ± 4.3 | 0.99 ± 3.7 |
Change in thrombocytes (measured in 10\^9 cells per liter) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.
| ratio of thrombocytes | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Change from week 0 to week 54 | 0.98 ± 14.5 | 0.98 ± 15.0 | 1.03 ± 13.2 | 0.98 ± 14.1 |
| Change from week 0 to week 80 | 1.00 ± 15.0 | 1.03 ± 15.7 | 1.04 ± 15.6 | 1.00 ± 17.3 |
Change in eosinophil (measured in percentage '%') from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.
| Ratio of eosinophils | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Change from week 0 to week 54 | 1.15 ± 0.65 | 1.30 ± 1.71 | 3.10 ± 13.79 | 1.37 ± 1.15 |
| Change from week 0 to week 80 | 1.31 ± 1.24 | 1.23 ± 1.03 | 1.54 ± 1.78 | 1.36 ± 1.27 |
Change in neutrophils (measured in percentage '%') from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.
| ratio of neutrophils | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Change from week 0 to week 54 | 0.98 ± 18.8 | 0.99 ± 17.6 | 0.97 ± 18.5 | 1.04 ± 17.8 |
| Change from week 0 to week 80 | 0.97 ± 17.5 | 0.99 ± 14.2 | 0.98 ± 20.7 | 1.04 ± 17.2 |
Change in basophils (measured in percentage '%') from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.
| Ratio of basophils | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Change from week 0 to week 54 | 1.73 ± 2.11 | 1.58 ± 1.52 | 1.52 ± 1.47 | 1.43 ± 1.06 |
| Change from week 0 to week 80 | 2.17 ± 2.17 | 1.73 ± 1.41 | 2.09 ± 1.86 | 1.96 ± 1.27 |
Change in lymphocytes (measured in percentage '%') from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.
| ratio of lymphocytes | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Change from week 0 to week 54 | 1.00 ± 28.5 | 1.00 ± 28.3 | 1.02 ± 28.4 | 0.91 ± 30.7 |
| Change from week 0 to week 80 | 1.01 ± 28.0 | 0.98 ± 21.8 | 0.99 ± 35.1 | 0.91 ± 30.6 |
Change in monocytes (measured in percentage '%') from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.
| ratio of monocytes | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Change from week 0 to week 54 | 1.05 ± 40.8 | 1.02 ± 34.8 | 1.01 ± 41.1 | 1.01 ± 34.9 |
| Change from week 0 to week 80 | 1.12 ± 44.0 | 1.07 ± 37.5 | 1.04 ± 42.9 | 1.12 ± 35.4 |
Change in ALAT (measured in units per liter \[U/L\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.
| ratio of ALT | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Change from week 0 to week 54 | 0.96 ± 47.7 | 0.98 ± 35.9 | 0.97 ± 46.0 | 0.90 ± 44.1 |
| Change from week 0 to week 80 | 0.95 ± 54.7 | 0.98 ± 39.5 | 1.06 ± 40.7 | 0.92 ± 40.6 |
Change in albumin (measured in gram per deciliter \[g/dL\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.
| ratio of albumin | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Change from week 0 to week 54 | 0.99 ± 7.3 | 1.00 ± 6.00 | 1.02 ± 7.4 | 0.99 ± 7.5 |
| Change from week 0 to week 80 | 1.00 ± 6.7 | 1.01 ± 6.9 | 1.00 ± 6.7 | 0.99 ± 6.9 |
Change in amylase (measured in units per liter \[U/L\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.
| ratio of Amylase | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Change from week 0 to week 54 | 1.07 ± 20.7 | 0.98 ± 16.6 | 1.04 ± 18.9 | 1.01 ± 19.2 |
| Change from week 0 to week 80 | 1.04 ± 24.3 | 0.99 ± 14.9 | 1.03 ± 19.8 | 1.04 ± 26.1 |
Change in ALP (measured in units per liter \[U/L\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.
| Ratio of ALP | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Change from week 0 to week 54 | 1.03 ± 28.6 | 0.99 ± 17.8 | 0.99 ± 18.1 | 1.03 ± 17.9 |
| Change from week 0 to week 80 | 1.07 ± 30.3 | 1.05 ± 16.5 | 1.04 ± 22.1 | 1.04 ± 21.7 |
Change in ASAT (measured in units per liter \[U/L\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.
| Ratio of AST | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Change from week 0 to week 54 | 0.99 ± 39.3 | 0.99 ± 34.5 | 1.00 ± 57.0 | 0.98 ± 43.1 |
| Change from week 0 to week 80 | 0.98 ± 39.1 | 0.98 ± 32.4 | 1.09 ± 34.6 | 0.99 ± 39.3 |
Change in Total bilirubin (measured in micromole per liter \[umol/L\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.
| ratio of total bilirubin | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Change from week 0 to week 54 | 0.81 ± 61.7 | 1.10 ± 56.5 | 0.99 ± 49.8 | 1.01 ± 59.4 |
| Change from week 0 to week 80 | 0.91 ± 44.7 | 1.04 ± 74.8 | 0.98 ± 55.1 | 0.99 ± 58.7 |
Change in calcium corrected (measured in millimole per liter \[mmol/L\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.
| ratio of calcium | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Change from week 0 to week 54 | 0.99 ± 3.7 | 0.98 ± 3.6 | 0.98 ± 4.0 | 0.99 ± 4.2 |
| Change from week 0 to week 80 | 0.96 ± 3.5 | 0.97 ± 4.0 | 0.98 ± 3.9 | 0.98 ± 4.0 |
Change in chloride (measured in millimole per liter \[mmol/L\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.
| ratio of chloride | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Change from week 0 to week 54 | 1.01 ± 2.4 | 1.00 ± 2.2 | 1.00 ± 2.8 | 1.00 ± 3.1 |
| Change from week 0 to week 80 | 1.00 ± 2.3 | 1.01 ± 2.7 | 1.00 ± 3.0 | 1.00 ± 3.0 |
Change in creatine kinase (measured in units per liter \[U/L\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.
| Ratio of Creatine Kinase | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Change from week 0 to week 54 | 1.16 ± 86.3 | 1.17 ± 64.5 | 1.08 ± 140.2 | 1.02 ± 72.8 |
| Change from week 0 to week 80 | 1.11 ± 48.1 | 1.09 ± 68.3 | 1.24 ± 87.2 | 1.13 ± 76.5 |
Change in creatinine (measured in micromole per liter \[umol/L\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.
| Ratio of Creatinine | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Change from week 0 to week 54 | 1.01 ± 12.0 | 1.05 ± 10.6 | 1.04 ± 12.8 | 1.01 ± 9.9 |
| Change from week 0 to week 80 | 1.02 ± 11.2 | 1.05 ± 14.3 | 1.05 ± 13.1 | 1.02 ± 12.3 |
Change in GGT (measured in units per liter \[U/L\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.
| Ratio of GGT | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Change from week 0 to week 54 | 1.02 ± 38.6 | 1.08 ± 27.7 | 1.03 ± 37.2 | 1.02 ± 41.8 |
| Change from week 0 to week 80 | 1.05 ± 41.9 | 1.13 ± 29.4 | 1.10 ± 41.1 | 1.00 ± 36.8 |
Change in C-reactive protein serum (measured in milligrams per liter \[mg/L\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.
| Ratio of C-reactive protein | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Change from week 0 to week 54 | 0.92 ± 141.6 | 1.04 ± 93.0 | 0.89 ± 87.8 | 1.06 ± 78.0 |
| Change from week 0 to week 80 | 1.08 ± 103.8 | 0.94 ± 81.0 | 1.25 ± 134.7 | 1.06 ± 70.1 |
Change in Lactate Dehydrogenase (measured in units per liter \[U/L\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.
| Ratio of Lactate Dehydrogenase | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Change from week 0 to week 54 | 0.99 ± 12.6 | 1.03 ± 18.4 | 1.04 ± 23.3 | 1.03 ± 16.5 |
| Change from week 0 to week 80 | 1.02 ± 12.1 | 1.04 ± 19.6 | 1.09 ± 19.3 | 1.03 ± 17.8 |
Change in lipase (measured in units per liter \[U/L\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.
| Ratio of lipase | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Change from week 0 to week 54 | 1.49 ± 36.6 | 1.00 ± 27.4 | 1.34 ± 36.2 | 1.01 ± 29.4 |
| Change from week 0 to week 80 | 1.05 ± 40.4 | 0.94 ± 27.2 | 1.02 ± 26.5 | 0.96 ± 37.2 |
Change in magnesium (measured in millimole per liter \[mmol/L\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.
| Ratio of magnesium | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Change from week 0 to week 54 | 1.02 ± 8.9 | 1.01 ± 7.6 | 1.02 ± 7.8 | 0.99 ± 8.1 |
| Change from week 0 to week 80 | 1.01 ± 10.7 | 1.03 ± 11.2 | 1.02 ± 9.0 | 0.98 ± 9.2 |
Change in phosphate (measured in millimole per liter \[mmol/L\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.
| Ratio of phosphate | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Change from week 0 to week 54 | 0.99 ± 16.0 | 0.99 ± 16.6 | 1.02 ± 13.9 | 0.96 ± 18.6 |
| Change from week 0 to week 80 | 1.02 ± 20.5 | 1.01 ± 16.9 | 1.03 ± 19.9 | 0.99 ± 17.4 |
Change in potassium (measured in millimole per liter \[mmol/L\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.
| Ratio of potassium | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Change from week 0 to week 54 | 1.01 ± 8.1 | 0.98 ± 6.9 | 0.99 ± 8.3 | 0.98 ± 10.4 |
| Change from week 0 to week 80 | 0.99 ± 8.3 | 0.99 ± 6.9 | 0.98 ± 8.5 | 0.98 ± 10.0 |
Change in sodium (measured in millimole per liter \[mmol/L\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.
| Ratio of sodium | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Change from week 0 to week 54 | 1.00 ± 1.9 | 1.00 ± 1.4 | 1.00 ± 1.9 | 1.00 ± 2.0 |
| Change from week 0 to week 80 | 0.99 ± 1.8 | 1.00 ± 2.1 | 1.00 ± 2.3 | 1.00 ± 1.8 |
Change in total protein (measured in gram per liter \[g/dL\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.
| Ratio of total protein | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Change from week 0 to week 54 | 0.99 ± 6.8 | 1.00 ± 6.0 | 1.01 ± 7.2 | 1.00 ± 7.6 |
| Change from week 0 to week 80 | 0.99 ± 6.5 | 1.00 ± 6.4 | 1.00 ± 6.6 | 1.00 ± 7.4 |
Change in blood urea nitrogen serum (measured in milligram per deciliter \[mg/dL\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.
| Ratio of Blood Urea Nitrogen serum | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Change from week 0 to week 54 | 1.00 ± 27.0 | 1.05 ± 22.4 | 0.98 ± 22.0 | 0.94 ± 23.3 |
| Change from week 0 to week 80 | 0.97 ± 33.2 | 0.97 ± 26.2 | 0.98 ± 28.9 | 0.97 ± 28.2 |
Change in Uric Acid (measured in milligram per deciliter \[mg/dL\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.
| Ratio of uric acid | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Change from week 0 to week 54 | 0.93 ± 21.3 | 0.98 ± 17.6 | 0.98 ± 18.8 | 0.96 ± 18.0 |
| Change from week 0 to week 80 | 0.95 ± 17.1 | 0.94 ± 19.1 | 0.96 ± 22.2 | 0.95 ± 19.6 |
Change in INR (measured in ratio\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.
| Ratio of INR | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Change from week 0 to week 54 | 0.97 ± 9.5 | 0.96 ± 10.4 | 0.95 ± 9.8 | 0.96 ± 13.7 |
| Change from week 0 to week 80 | 0.98 ± 12.4 | 0.99 ± 12.9 | 0.96 ± 9.2 | 0.97 ± 11.5 |
Change in D-Dimer (measured in mg/L) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.
| Ratio of D-dimer | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Change from week 0 to week 54 | 0.96 ± 37.6 | 0.98 ± 53.9 | 0.98 ± 56.8 | 1.15 ± 107.1 |
| Change from week 0 to week 80 | 0.96 ± 43.7 | 0.92 ± 61.3 | 1.05 ± 60.0 | 1.10 ± 74.3 |
Change in total cholesterol (measured in mmol/L) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.
| Ratio of total cholesterol | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Change from week 0 to week 54 | 1.00 ± 13.8 | 1.02 ± 14.1 | 1.03 ± 16.2 | 1.04 ± 16.8 |
| Change from week 0 to week 80 | 1.02 ± 15.5 | 1.03 ± 14.1 | 1.07 ± 15.0 | 1.03 ± 18.4 |
Change in total free fatty acids (measured in mmol/L) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.
| Ratio of free fatty acids | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Change from week 0 to week 54 | 0.86 ± 94.5 | 1.01 ± 114.4 | 1.18 ± 82.5 | 0.97 ± 68.7 |
| Change from week 0 to week 80 | 0.89 ± 85.3 | 1.06 ± 112.8 | 1.19 ± 92.8 | 0.94 ± 84.0 |
Change in HDL cholesterol (measured in mmol/L) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.
| Ratio of HDL cholesterol | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Change from week 0 to week 54 | 1.04 ± 17.3 | 1.08 ± 18.2 | 1.12 ± 19.6 | 1.10 ± 20.2 |
| Change from week 0 to week 80 | 1.04 ± 18.7 | 1.06 ± 16.7 | 1.14 ± 21.5 | 1.07 ± 22.2 |
Change in LDL cholesterol (measured in mmol/L) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.
| Ratio of LDL cholesterol | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Change from week 0 to week 54 | 0.96 ± 17.8 | 0.97 ± 20.9 | 0.98 ± 24.0 | 1.01 ± 23.6 |
| Change from week 0 to week 80 | 0.99 ± 22.2 | 1.02 ± 21.2 | 1.02 ± 21.2 | 1.03 ± 29.2 |
Change in Triglycerides (measured in mmol/L) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.
| Ratio of TG | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Change from week 0 to week 54 | 1.03 ± 46.2 | 0.96 ± 39.5 | 1.03 ± 49.2 | 1.02 ± 54.7 |
| Change from week 0 to week 80 | 1.08 ± 45.6 | 0.94 ± 45.1 | 1.09 ± 51.5 | 0.95 ± 50.4 |
Change in IgE (measured in kilo international units per liter \[kIU/L\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.
| Ratio of IgE | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Change from week 0 to week 54 | 1.31 ± 71.6 | 1.05 ± 63.1 | 1.08 ± 45.7 | 1.02 ± 41.8 |
| Change from week 0 to week 80 | 1.32 ± 65.4 | 1.18 ± 38.5 | 1.16 ± 55.1 | 0.94 ± 61.2 |
Urinalysis was performed by urine dipsticks for protein, glucose, erythrocytes, ketones leukocytes, nitrite, pH and specific gravity and categorised as normal, abnormal not clinically significant (NCS) and abnormal clinially significant (CS). Number of participants in each category at baseline (week 0), week 54 and 80 are presented.
| Participants | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Week 0: Glucose dipstick — Normal | 72 | 71 | 67 | 71 |
| Week 0: Glucose dipstick — Abnormal, NCS | 5 | 6 | 9 | 6 |
| Week 0: Glucose dipstick — Abnormal, CS | 0 | 0 | 0 | 0 |
| Week 54: Glucose dipstick — Normal | 57 | 56 | 63 | 59 |
| Week 54: Glucose dipstick — Abnormal, NCS | 9 | 9 | 5 | 6 |
| Week 54: Glucose dipstick — Abnormal, CS | 2 | 0 | 0 | 0 |
| Week 80: Glucose dipstick — Normal | 54 | 54 | 54 | 51 |
| Week 80: Glucose dipstick — Abnormal, NCS | 12 | 10 | 13 | 11 |
| Week 80: Glucose dipstick — Abnormal, CS | 0 | 0 | 1 | 0 |
| Week 0: Ketone dipstick — Normal | 74 | 73 | 73 | 76 |
| Week 0: Ketone dipstick — Abnormal, NCS | 2 | 4 | 3 | 1 |
| Week 0: Ketone dipstick — Abnormal, CS | 1 | 0 | 0 | 0 |
| Week 54: Ketone dipstick — Normal | 68 | 64 | 65 | 64 |
| Week 54: Ketone dipstick — Abnormal, NCS | 0 | 1 | 3 | 1 |
| Week 54: Ketone dipstick — Abnormal, CS | 0 | 0 | 0 | 0 |
| Week 80: Ketone dipstick — Normal | 65 | 61 | 66 | 61 |
| Week 80: Ketone dipstick — Abnormal, NCS | 1 | 3 | 1 | 1 |
| Week 80: Ketone dipstick — Abnormal, CS | 0 | 0 | 1 | 0 |
| Week 0: pH dipstick — Normal | 75 | 77 | 76 | 75 |
| Week 0: pH dipstick — Abnormal, NCS | 2 | 0 | 0 | 2 |
| Week 0: pH dipstick — Abnormal, CS | 0 | 0 | 0 | 0 |
| Week 54: pH dipstick — Normal | 67 | 65 | 68 | 64 |
| Week 54: pH dipstick — Abnormal, NCS | 1 | 0 | 0 | 1 |
| Week 54: pH dipstick — Abnormal, CS | 0 | 0 | 0 | 0 |
| Week 80: pH dipstick — Normal | 66 | 64 | 68 | 62 |
| Week 80: pH dipstick — Abnormal, NCS | 0 | 0 | 0 | 0 |
| Week 80: pH dipstick — Abnormal, CS | 0 | 0 | 0 | 0 |
| Week 0: Erythrocytes in urine — Normal | 74 | 74 | 74 | 72 |
| Week 0: Erythrocytes in urine — Abnormal, NCS | 2 | 3 | 2 | 4 |
| Week 0: Erythrocytes in urine — Abnormal, CS | 1 | 0 | 0 | 1 |
| Week 54: Erythrocytes in urine — Normal | 66 | 63 | 66 | 63 |
| Week 54: Erythrocytes in urine — Abnormal, NCS | 2 | 2 | 2 | 2 |
| Week 54: Erythrocytes in urine — Abnormal, CS | 0 | 0 | 0 | 0 |
| Week 80: Erythrocytes in urine — Normal | 63 | 61 | 65 | 60 |
| Week 80: Erythrocytes in urine — Abnormal, NCS | 3 | 3 | 3 | 2 |
| Week 80: Erythrocytes in urine — Abnormal, CS | 0 | 0 | 0 | 0 |
| Week 0: Leukocytes in urine — Normal | 77 | 73 | 76 | 77 |
| Week 0: Leukocytes in urine — Abnormal, NCS | 0 | 4 | 0 | 0 |
| Week 0: Leukocytes in urine — Abnormal, CS | 0 | 0 | 0 | 0 |
| Week 54: Leukocytes in urine — Normal | 64 | 62 | 67 | 64 |
| Week 54: Leukocytes in urine — Abnormal, NCS | 4 | 3 | 1 | 1 |
| Week 54: Leukocytes in urine — Abnormal, CS | 0 | 0 | 0 | 0 |
| Week 80: Leukocytes in urine — Normal | 62 | 61 | 67 | 60 |
| Week 80: Leukocytes in urine — Abnormal, NCS | 4 | 3 | 1 | 2 |
| Week 80: Leukocytes in urine — Abnormal, CS | 0 | 0 | 0 | 0 |
| Week 0: Nitrite — Normal | 77 | 77 | 76 | 77 |
| Week 0: Nitrite — Abnormal, NCS | 0 | 0 | 0 | 0 |
| Week 0: Nitrite — Abnormal, CS | 0 | 0 | 0 | 0 |
| Week 54: Nitrite — Normal | 68 | 65 | 68 | 65 |
| Week 54: Nitrite — Abnormal, NCS | 0 | 0 | 0 | 0 |
| Week 54: Nitrite — Abnormal, CS | 0 | 0 | 0 | 0 |
| Week 80: Nitrite — Normal | 65 | 64 | 68 | 61 |
| Week 80: Nitrite — Abnormal, NCS | 1 | 0 | 0 | 1 |
| Week 80: Nitrite — Abnormal, CS | 0 | 0 | 0 | 0 |
| Week 0: Protein urine — Normal | 77 | 71 | 75 | 76 |
| Week 0: Protein urine — Abnormal, NCS | 0 | 6 | 1 | 1 |
| Week 0: Protein urine — Abnormal, CS | 0 | 0 | 0 | 0 |
| Week 54: Protein urine — Normal | 67 | 64 | 62 | 61 |
| Week 54: Protein urine — Abnormal, NCS | 1 | 1 | 6 | 4 |
| Week 54: Protein urine — Abnormal, CS | 0 | 0 | 0 | 0 |
| Week 80: Protein urine — Normal | 63 | 62 | 65 | 59 |
| Week 80: Protein urine — Abnormal, NCS | 3 | 1 | 3 | 2 |
| Week 80: Protein urine — Abnormal, CS | 0 | 1 | 0 | 1 |
| Week 0: Specific Gravity — Normal | 75 | 77 | 76 | 75 |
| Week 0: Specific Gravity — Abnormal, NCS | 2 | 0 | 0 | 2 |
| Week 0: Specific Gravity — Abnormal, CS | 0 | 0 | 0 | 0 |
| Week 54: Specific Gravity — Normal | 67 | 65 | 68 | 64 |
| Week 54: Specific Gravity — Abnormal, NCS | 1 | 0 | 0 | 1 |
| Week 54: Specific Gravity — Abnormal, CS | 0 | 0 | 0 | 0 |
| Week 80: Specific Gravity — Normal | 65 | 64 | 68 | 62 |
| Week 80: Specific Gravity — Abnormal, NCS | 1 | 0 | 0 | 0 |
| Week 80: Specific Gravity — Abnormal, CS | 0 | 0 | 0 | 0 |
IL-6 levels at baseline (week 0), weeks 54 and 80 are evaluated and presented.
| picogram per milliliter (pg/mL) | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Week 0 | 0.9 ± 0.6 | 0.8 ± 0.1 | 1.2 ± 1.8 | 0.8 ± 0.3 |
| Week 54 | 0.8 ± 0.3 | 0.8 ± 0.4 | 1.0 ± 0.8 | 0.8 ± 0.2 |
| Week 80 | 0.9 ± 0.4 | 0.8 ± 0.2 | 0.9 ± 0.8 | 0.9 ± 0.4 |
IL-10 levels at baseline (week 0), weeks 54 and 80 are evaluated and presented.
| pg/mL | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Week 0 | 0.7 ± 1.4 | 0.5 ± 1.1 | 0.4 ± 0.3 | 0.4 ± 0.2 |
| Week 54 | 0.4 ± 0.2 | 0.4 ± 0.1 | 0.4 ± 0.3 | 0.4 ± 0.3 |
| Week 80 | 0.4 ± 0.5 | 0.4 ± 0.2 | 0.5 ± 0.7 | 0.4 ± 0.1 |
IL-17 levels at baseline (week 0), weeks 54 and 80 are evaluated and presented.
| pg/mL | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Week 0 | 4.9 ± 2.0 | 4.7 ± 0.7 | 4.7 ± 0.0 | 4.8 ± 0.9 |
| Week 54 | 4.9 ± 1.9 | 4.8 ± 1.3 | 5.1 ± 3.5 | 5.4 ± 5.0 |
| Week 80 | 4.9 ± 1.7 | 4.7 ± 0.0 | 4.8 ± 1.2 | 4.8 ± 1.0 |
IFN gamma levels at baseline (week 0), weeks 54 and 80 are evaluated and presented.
| pg/mL | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Week 0 | 7.3 ± 16.1 | 7.8 ± 24.0 | 5.8 ± 11.6 | 4.3 ± 2.8 |
| Week 54 | 4.6 ± 4.2 | 7.5 ± 19.6 | 5.0 ± 6.8 | 5.8 ± 7.0 |
| Week 80 | 4.4 ± 2.8 | 4.9 ± 6.4 | 13.0 ± 57.5 | 4.5 ± 3.4 |
TNF-alpha levels at baseline (week 0), weeks 54 and 80 are evaluated and presented.
| pg/mL | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Week 0 | 2.60 ± 1.69 | 2.32 ± 0.82 | 2.70 ± 1.73 | 3.06 ± 3.75 |
| Week 54 | 2.36 ± 0.75 | 2.33 ± 0.59 | 2.56 ± 1.11 | 2.43 ± 0.65 |
| Week 80 | 2.43 ± 0.66 | 2.36 ± 0.68 | 2.96 ± 2.39 | 2.75 ± 2.47 |
Change in TSH (measured in milli international units per liter \[mIU/L\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.
| Ratio of Thyroid Stimulating Hormone | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Change from week 0 to week 54 | 1.00 ± 49.9 | 1.12 ± 54.1 | 0.89 ± 46.6 | 0.91 ± 66.1 |
| Change from week 0 to week 80 | 1.04 ± 46.7 | 0.99 ± 116.1 | 0.99 ± 48.5 | 0.93 ± 84.5 |
Change in Calcitonin (measured in nanogram per liter \[ng/L\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.
| Ratio of Calcitonin | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Change from week 0 to week 54 | 1.00 ± 43.5 | 0.90 ± 48.5 | 0.89 ± 57.2 | 0.88 ± 47.4 |
| Change from week 0 to week 80 | 0.85 ± 50.9 | 0.93 ± 41.8 | 0.82 ± 71.5 | 0.90 ± 64.5 |
Change in systolic blood pressure (SBP) and diastolic blood pressure (DBP) are evaluated from baseline (week 0) to weeks 54 and 80.
| Millimeters of mercury (mmHg) | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Week 54: Systolic blood pressure | -3 ± 9 | 3 ± 9 | -2 ± 14 | 1 ± 11 |
| Week 80: Systolic blood pressure | -1 ± 10 | 2 ± 11 | 1 ± 12 | 4 ± 10 |
| Week 54: Diastolic blood pressure | -0 ± 9 | 2 ± 9 | -1 ± 10 | -1 ± 8 |
| Week 80: Diastolic blood pressure | -0 ± 9 | 2 ± 9 | 1 ± 10 | 1 ± 10 |
Change in pulse is evaluated from baseline (week 0) to weeks 54 and 80
| Beats/min | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Change from week 0 to week 54 | 3 ± 12 | 0 ± 12 | 6 ± 9 | 2 ± 8 |
| Change from week 0 to week 80 | -1 ± 10 | -1 ± 10 | 2 ± 10 | 1 ± 9 |
Change in body temperature is evaluated from baseline (week 0) to weeks 54 and 80.
| Degree celsius (C) | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Change from week 0 to week 54 | -0.1 ± 0.4 | 0.0 ± 0.6 | -0.1 ± 0.5 | -0.0 ± 0.3 |
| Change from week 0 to week 80 | -0.0 ± 0.4 | 0.1 ± 0.5 | 0.0 ± 0.5 | 0.0 ± 0.4 |
Change in respiratory rate is evaluated from baseline (week 0) to weeks 54 and 80.
| Breaths per minute | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Change from week 0 to week 54 | -0.3 ± 2.2 | 0.1 ± 3.0 | 0.1 ± 2.5 | 0.6 ± 2.4 |
| Change from week 0 to week 80 | -0.3 ± 2.0 | -0.2 ± 2.7 | 0.1 ± 2.5 | 0.1 ± 2.2 |
The ECG was assessed by the investigator at baseline (week 0), week 54 and week 80 and categorised as normal, abnormal NCS or abnormal CS. Number of participants in each ECG category at baseline, week 54 and week 80 are presented.
| Participants | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Week 0 — Normal | 62 | 65 | 60 | 63 |
| Week 0 — Abnormal, NCS | 15 | 12 | 16 | 13 |
| Week 0 — Abnormal, CS | 0 | 0 | 0 | 1 |
| Week 54 — Normal | 54 | 48 | 55 | 46 |
| Week 54 — Abnormal, NCS | 14 | 17 | 12 | 19 |
| Week 54 — Abnormal, CS | 0 | 0 | 0 | 0 |
| Week 80 — Normal | 51 | 48 | 53 | 50 |
| Week 80 — Abnormal, NCS | 15 | 16 | 15 | 12 |
| Week 80 — Abnormal, CS | 0 | 0 | 0 | 0 |
Dilated fundoscopy or fundus photography was performed by the investigator at week 0, week 54 and week 80. The results of the examination were interpreted for each eye (left/right) are categorised as normal, abnormal NCS or abnormal CS. Number of participants in each category at week 0, week 54 and week 80 are presented.
| Participants | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Week 0: Left eye ophthalmoscopy — Normal | 64 | 68 | 70 | 66 |
| Week 0: Left eye ophthalmoscopy — Abnormal, NCS | 13 | 9 | 6 | 11 |
| Week 0: Left eye ophthalmoscopy — Abnormal, CS | 0 | 0 | 0 | 0 |
| Week 54: Left eye ophthalmoscopy — Normal | 55 | 56 | 60 | 54 |
| Week 54: Left eye ophthalmoscopy — Abnormal, NCS | 12 | 7 | 9 | 9 |
| Week 54: Left eye ophthalmoscopy — Abnormal, CS | 1 | 0 | 0 | 1 |
| Week 80: Left eye ophthalmoscopy — Normal | 52 | 54 | 59 | 51 |
| Week 80: Left eye ophthalmoscopy — Abnormal, NCS | 11 | 8 | 6 | 8 |
| Week 80: Left eye ophthalmoscopy — Abnormal, CS | 3 | 0 | 0 | 0 |
| Week 0: Right eye ophthalmoscopy — Normal | 58 | 66 | 69 | 67 |
| Week 0: Right eye ophthalmoscopy — Abnormal, NCS | 18 | 11 | 7 | 10 |
| Week 0: Right eye ophthalmoscopy — Abnormal, CS | 1 | 0 | 0 | 0 |
| Week 54: Right eye ophthalmoscopy — Normal | 55 | 55 | 60 | 55 |
| Week 54: Right eye ophthalmoscopy — Abnormal, NCS | 13 | 8 | 9 | 8 |
| Week 54: Right eye ophthalmoscopy — Abnormal, CS | 0 | 0 | 0 | 1 |
| Week 80: Right eye ophthalmoscopy — Normal | 52 | 53 | 58 | 51 |
| Week 80: Right eye ophthalmoscopy — Abnormal, NCS | 12 | 9 | 7 | 8 |
| Week 80: Right eye ophthalmoscopy — Abnormal, CS | 2 | 0 | 0 | 0 |
Physical examination parameters are categorised as general appearance; head, ears, eyes, nose, throat, neck; respiratory system;cardiovascular system; gastrointestinal system including mouth; musculoskeletal system; central and peripheral nervous system; skin; lymph node palpation and thyroid gland. Investigator assessed the participants with normal, abnormal not clinically significant (NCS) and abnormal clinically significant (CS) findings at week 0, week 54 and week 80 are presented.
| Participants | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Week 0: General Appearance — Normal | 76 | 77 | 76 | 76 |
| Week 0: General Appearance — Abnormal, NCS | 1 | 0 | 0 | 1 |
| Week 0: General Appearance — Abnormal, CS | 0 | 0 | 0 | 0 |
| Week 54: General Appearance — Normal | 68 | 64 | 66 | 65 |
| Week 54: General Appearance — Abnormal, NCS | 0 | 0 | 0 | 1 |
| Week 54: General Appearance — Abnormal, CS | 0 | 1 | 0 | 0 |
| Week 80: General Appearance — Normal | 67 | 64 | 68 | 61 |
| Week 80: General Appearance — Abnormal, NCS | 0 | 0 | 0 | 1 |
| Week 80: General Appearance — Abnormal, CS | 0 | 0 | 0 | 0 |
| Week 0: Head, Ears, Eyes, Nose, Throat, Neck — Normal | 75 | 77 | 76 | 76 |
| Week 0: Head, Ears, Eyes, Nose, Throat, Neck — Abnormal, NCS | 2 | 0 | 0 | 1 |
| Week 0: Head, Ears, Eyes, Nose, Throat, Neck — Abnormal, CS | 0 | 0 | 0 | 0 |
| Week 54: Head, Ears, Eyes, Nose, Throat, Neck — Normal | 66 | 65 | 66 | 66 |
| Week 54: Head, Ears, Eyes, Nose, Throat, Neck — Abnormal, NCS | 1 | 0 | 0 | 0 |
| Week 54: Head, Ears, Eyes, Nose, Throat, Neck — Abnormal, CS | 1 | 0 | 0 | 0 |
| Week 80: Head, Ears, Eyes, Nose, Throat, Neck — Normal | 65 | 64 | 66 | 60 |
| Week 80: Head, Ears, Eyes, Nose, Throat, Neck — Abnormal, NCS | 2 | 0 | 2 | 2 |
| Week 80: Head, Ears, Eyes, Nose, Throat, Neck — Abnormal, CS | 0 | 0 | 0 | 0 |
| Week 0: Respiratory System — Normal | 77 | 77 | 76 | 77 |
| Week 0: Respiratory System — Abnormal, NCS | 0 | 0 | 0 | 0 |
| Week 0: Respiratory System — Abnormal, CS | 0 | 0 | 0 | 0 |
| Week 54: Respiratory System — Normal | 68 | 65 | 66 | 66 |
| Week 54: Respiratory System — Abnormal, NCS | 0 | 0 | 0 | 0 |
| Week 54: Respiratory System — Abnormal, CS | 0 | 0 | 0 | 0 |
| Week 80: Respiratory System — Normal | 67 | 64 | 68 | 61 |
| Week 80: Respiratory System — Abnormal, NCS | 0 | 0 | 0 | 1 |
| Week 80: Respiratory System — Abnormal, CS | 0 | 0 | 0 | 0 |
| Week 0: Cardiovascular System — Normal | 74 | 76 | 76 | 73 |
| Week 0: Cardiovascular System — Abnormal, NCS | 3 | 1 | 0 | 4 |
| Week 0: Cardiovascular System — Abnormal, CS | 0 | 0 | 0 | 0 |
| Week 54: Cardiovascular System — Normal | 67 | 65 | 65 | 66 |
| Week 54: Cardiovascular System — Abnormal, NCS | 1 | 0 | 1 | 0 |
| Week 54: Cardiovascular System — Abnormal, CS | 0 | 0 | 0 | 0 |
| Week 80: Cardiovascular System — Normal | 67 | 64 | 67 | 62 |
| Week 80: Cardiovascular System — Abnormal, NCS | 0 | 0 | 1 | 0 |
| Week 80: Cardiovascular System — Abnormal, CS | 0 | 0 | 0 | 0 |
| Week 0: Gastrointestinal System incl. Mouth — Normal | 75 | 76 | 76 | 76 |
| Week 0: Gastrointestinal System incl. Mouth — Abnormal, NCS | 2 | 1 | 0 | 1 |
| Week 0: Gastrointestinal System incl. Mouth — Abnormal, CS | 0 | 0 | 0 | 0 |
| Week 54: Gastrointestinal System incl. Mouth — Normal | 68 | 64 | 66 | 65 |
| Week 54: Gastrointestinal System incl. Mouth — Abnormal, NCS | 0 | 1 | 0 | 1 |
| Week 54: Gastrointestinal System incl. Mouth — Abnormal, CS | 0 | 0 | 0 | 0 |
| Week 80: Gastrointestinal System incl. Mouth — Normal | 67 | 63 | 68 | 61 |
| Week 80: Gastrointestinal System incl. Mouth — Abnormal, NCS | 0 | 1 | 0 | 1 |
| Week 80: Gastrointestinal System incl. Mouth — Abnormal, CS | 0 | 0 | 0 | 0 |
| Week 0: Musculoskeletal System — Normal | 76 | 75 | 74 | 77 |
| Week 0: Musculoskeletal System — Abnormal, NCS | 1 | 2 | 2 | 0 |
| Week 0: Musculoskeletal System — Abnormal, CS | 0 | 0 | 0 | 0 |
| Week 54: Musculoskeletal System — Normal | 65 | 63 | 66 | 65 |
| Week 54: Musculoskeletal System — Abnormal, NCS | 1 | 2 | 0 | 1 |
| Week 54: Musculoskeletal System — Abnormal, CS | 2 | 0 | 0 | 0 |
| Week 80: Musculoskeletal System — Normal | 66 | 64 | 68 | 62 |
| Week 80: Musculoskeletal System — Abnormal, NCS | 1 | 0 | 0 | 0 |
| Week 80: Musculoskeletal System — Abnormal, CS | 0 | 0 | 0 | 0 |
| Week 0: Central and Peripheral Nervous System — Normal | 77 | 76 | 76 | 76 |
| Week 0: Central and Peripheral Nervous System — Abnormal, NCS | 0 | 1 | 0 | 1 |
| Week 0: Central and Peripheral Nervous System — Abnormal, CS | 0 | 0 | 0 | 0 |
| Week 54: Central and Peripheral Nervous System — Normal | 68 | 64 | 66 | 65 |
| Week 54: Central and Peripheral Nervous System — Abnormal, NCS | 0 | 1 | 0 | 1 |
| Week 54: Central and Peripheral Nervous System — Abnormal, CS | 0 | 0 | 0 | 0 |
| Week 80: Central and Peripheral Nervous System — Normal | 66 | 63 | 68 | 62 |
| Week 80: Central and Peripheral Nervous System — Abnormal, NCS | 1 | 1 | 0 | 0 |
| Week 80: Central and Peripheral Nervous System — Abnormal, CS | 0 | 0 | 0 | 0 |
| Week 0: Skin — Normal | 70 | 75 | 69 | 74 |
| Week 0: Skin — Abnormal, NCS | 6 | 2 | 7 | 3 |
| Week 0: Skin — Abnormal, CS | 1 | 0 | 0 | 0 |
| Week 54: Skin — Normal | 61 | 63 | 63 | 66 |
| Week 54: Skin — Abnormal, NCS | 5 | 1 | 3 | 0 |
| Week 54: Skin — Abnormal, CS | 2 | 1 | 0 | 0 |
| Week 80: Skin — Normal | 61 | 62 | 65 | 62 |
| Week 80: Skin — Abnormal, NCS | 6 | 2 | 3 | 0 |
| Week 80: Skin — Abnormal, CS | 0 | 0 | 0 | 0 |
| Week 0: Lymph Node Palpation — Normal | 77 | 76 | 76 | 77 |
| Week 0: Lymph Node Palpation — Abnormal, NCS | 0 | 1 | 0 | 0 |
| Week 0: Lymph Node Palpation — Abnormal, CS | 0 | 0 | 0 | 0 |
| Week 54: Lymph Node Palpation — Normal | 68 | 65 | 66 | 64 |
| Week 54: Lymph Node Palpation — Abnormal, NCS | 0 | 0 | 0 | 1 |
| Week 54: Lymph Node Palpation — Abnormal, CS | 0 | 0 | 0 | 0 |
| Week 80: Lymph Node Palpation — Normal | 67 | 63 | 67 | 62 |
| Week 80: Lymph Node Palpation — Abnormal, NCS | 0 | 0 | 1 | 0 |
| Week 80: Lymph Node Palpation — Abnormal, CS | 0 | 0 | 0 | 0 |
| Week 0: Thyroid Gland — Normal | 77 | 76 | 76 | 75 |
| Week 0: Thyroid Gland — Abnormal, NCS | 0 | 1 | 0 | 2 |
| Week 0: Thyroid Gland — Abnormal, CS | 0 | 0 | 0 | 0 |
| Week 54: Thyroid Gland — Normal | 67 | 65 | 66 | 65 |
| Week 54: Thyroid Gland — Abnormal, NCS | 1 | 0 | 0 | 0 |
| Week 54: Thyroid Gland — Abnormal, CS | 0 | 0 | 0 | 0 |
| Week 80: Thyroid Gland — Normal | 67 | 64 | 68 | 62 |
| Week 80: Thyroid Gland — Abnormal, NCS | 0 | 0 | 0 | 0 |
| Week 80: Thyroid Gland — Abnormal, CS | 0 | 0 | 0 | 0 |
This outcome measure was applicable for NNC0114-0006 + Liraglutide treatment arm and NNC0114-0006 treatment arm. Participants was assessed for anti-NNC0114-0006 antibodies. Participant who reported anti-NNC0114-0006 antibodies were further analyzed for cross-reactivity. Number of participants who measured with anti-NNC0114-0006 antibodies at week 54 and week 80 are presented.
| Participants | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) |
|---|---|---|
| Week 0: Anti-NNC0114-0006 antibodies — Negative | 68 | 62 |
| Week 0: Anti-NNC0114-0006 antibodies — Positive | 9 | 14 |
| Week 0: Cross-reactivity — Negative | 4 | 7 |
| Week 0: Cross-reactivity — Positive | 5 | 7 |
| Week 54: Anti-NNC0114-0006 — Negative | 68 | 62 |
| Week 54: Anti-NNC0114-0006 — Positive | 0 | 3 |
| Week 54: Cross-reactivity — Negative | 0 | 3 |
| Week 54: Cross-reactivity — Positive | 0 | 0 |
| Week 80: Anti-NNC0114-0006 antibodies — Negative | 65 | 60 |
| Week 80: Anti-NNC0114-0006 antibodies — Positive | 2 | 4 |
| Week 80: Cross-reactivity — Negative | 1 | 2 |
| Week 80: Cross-reactivity — Positive | 1 | 2 |
This outcome measure is applicable for NNC0114-0006 + Liraglutide treatment arm and Liraglutide treatment arm. Participants was assessed for anti-liraglutide antibodies. Participant who reported anti-liraglutide antibodies were further analyzed for cross-reactivity. Number of participants who measured with anti-liraglutide antibodies at week 54 and week 80 are presented.
| Participants | NNC0114-0006 + Liraglutide (Experimental) | Liraglutide (Experimental) |
|---|---|---|
| Week 0: Anti-Liraglutide antibodies — Negative | 77 | 75 |
| Week 0: Anti-Liraglutide antibodies — Positive | 0 | 0 |
| Week 0: Cross-reactivity to native GLP-1 — Negative | 0 | 0 |
| Week 0: Cross-reactivity to native GLP-1 — Positive | 0 | 0 |
| Week 54: Anti-Liraglutide antibodies — Negative | 67 | 65 |
| Week 54: Anti-Liraglutide antibodies — Positive | 1 | 2 |
| Week 54: Cross-reactivity to native GLP-1 — Negative | 1 | 1 |
| Week 54: Cross-reactivity to native GLP-1 — Positive | 0 | 1 |
| Week 80: Anti-Liraglutide antibodies — Negative | 67 | 66 |
| Week 80: Anti-Liraglutide antibodies — Positive | 0 | 2 |
| Week 80: Cross-reactivity to native GLP-1 — Negative | 0 | 0 |
| Week 80: Cross-reactivity to native GLP-1 — Positive | 0 | 0 |
The total daily insulin dose was derived as the average of the doses reported on the three days prior to the visit. Change in daily total insulin dose from baseline (week 0) after 54 weeks of treatment and week 80 are presented.
| Units per kilograms | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Change from week 0 to week 54 | -0.05 ± 0.18 | 0.02 ± 0.18 | 0.01 ± 0.23 | 0.09 ± 0.19 |
| Change from week 0 to week 80 | 0.10 ± 0.20 | 0.05 ± 0.19 | 0.11 ± 0.22 | 0.12 ± 0.18 |
The number of insulin injections was derived as the average of the reported number on the three days prior to the visit. The change in number of insulin injections per day (count) from baseline (week 0) after 54 weeks of treatment and week 80 are presented.
| Injections per day | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Change from week 0 to week 54 | -0.3 ± 1.5 | -0.1 ± 1.2 | -0.5 ± 1.7 | 0.2 ± 1.4 |
| Change from week 0 to week 80 | 0.2 ± 1.5 | -0.3 ± 1.3 | -0.2 ± 1.5 | 0.2 ± 1.3 |
The number of weeks off bolus insulin after 54 weeks of treatment and week 80 are presented.
| Weeks | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Week 0 to week 54 | 10 ± 18 | 5 ± 14 | 9 ± 18 | 4 ± 11 |
| Week 0 to week 80 | 14 ± 25 | 9 ± 20 | 12 ± 24 | 6 ± 14 |
Change in glycosylated haemoglobin (HbA1c) is evaluated from baseline (week 0) to weeks 54 and 80.
| Percentage point of HbA1c | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Change from week 0 to week 54 | -0.7 ± 1.9 | -0.5 ± 1.4 | -0.3 ± 1.5 | -0.3 ± 1.9 |
| Change from week 0 to week 80 | -0.1 ± 1.6 | -0.2 ± 1.5 | 0.5 ± 2.1 | -0.4 ± 1.8 |
Change in fasting plasma glucose is evaluated from baseline (week 0) to weeks 54 and 80.
| mmol/L | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Change from week 0 to week 54 | 0.5 ± 3.2 | 0.2 ± 2.4 | -0.3 ± 3.1 | 0.5 ± 2.4 |
| Change from week 0 to week 80 | 1.1 ± 3.3 | 0.3 ± 2.4 | 0.2 ± 4.0 | 1.0 ± 2.4 |
Change in fasting C-peptide (measured in nanomole per liter \[nmol/L\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.
| Ratio of C-peptide | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Ratio from week 0 to week 54 | 1.01 ± 76.8 | 0.70 ± 71.1 | 0.65 ± 102.4 | 0.66 ± 116.3 |
| Ratio from week 0 to week 80 | 0.58 ± 112.9 | 0.53 ± 106.2 | 0.42 ± 132.5 | 0.54 ± 154.4 |
Change in fasting glucagon (measured in picogram per milliliter \[pg/mL\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.
| Ratio of glucagon | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Ratio from week 0 to week 54 | 1.01 ± 32.1 | 0.95 ± 32.5 | 0.96 ± 31.3 | 1.00 ± 31.4 |
| Ratio from week 0 to week 80 | 0.89 ± 36.2 | 0.85 ± 30.7 | 0.96 ± 32.8 | 0.93 ± 37.8 |
Participants measured plasma glucose values using the blood glucose meter at 7 time points: before breakfast, 90 minutes after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 minutes after start of dinner, bedtime. 7-point SMPG profile values are presented for week 54 and week 80.
| mmol/L | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Week 54: Before breakfast | 6.8 ± 3.4 | 6.8 ± 2.7 | 6.4 ± 2.2 | 6.3 ± 1.4 |
| Week 54: 90 minutes after start of breakfast | 8.9 ± 3.7 | 7.5 ± 2.4 | 7.4 ± 2.1 | 7.6 ± 2.4 |
| Week 54: Before lunch | 5.5 ± 1.8 | 6.4 ± 2.3 | 6.1 ± 1.8 | 6.0 ± 1.6 |
| Week 54: 90 minutes after start of lunch | 8.2 ± 2.6 | 7.5 ± 2.7 | 7.8 ± 2.4 | 7.7 ± 2.0 |
| Week 54: Before dinner | 6.5 ± 1.9 | 6.5 ± 2.5 | 6.6 ± 2.2 | 6.1 ± 1.7 |
| Week 54: 90 minutes after start of dinner | 8.2 ± 3.4 | 7.0 ± 2.5 | 7.2 ± 2.3 | 6.8 ± 1.9 |
| Week 54: Bedtime | 7.8 ± 3.9 | 7.4 ± 2.6 | 7.5 ± 2.5 | 7.2 ± 2.1 |
| Week 80: Before breakfast | 6.5 ± 1.7 | 6.4 ± 2.0 | 7.2 ± 2.7 | 6.8 ± 2.0 |
| Week 80: 90 minutes after start of breakfast | 8.5 ± 2.8 | 7.2 ± 3.0 | 8.3 ± 3.7 | 7.5 ± 2.7 |
| Week 80: Before lunch | 6.2 ± 2.2 | 6.2 ± 2.0 | 6.9 ± 3.3 | 6.1 ± 1.8 |
| Week 80: 90 minutes after start of lunch | 7.8 ± 2.6 | 7.6 ± 2.7 | 8.5 ± 4.5 | 8.0 ± 3.0 |
| Week 80: Before dinner | 6.5 ± 2.2 | 6.7 ± 2.9 | 7.6 ± 4.1 | 6.5 ± 1.6 |
| Week 80: 90 minutes after start of dinner | 7.6 ± 2.5 | 7.0 ± 2.1 | 9.0 ± 5.0 | 7.6 ± 2.5 |
| Week 80: Bedtime | 7.8 ± 3.0 | 6.6 ± 1.8 | 7.8 ± 4.4 | 7.4 ± 2.2 |
Participants measured plasma glucose values using the blood glucose meter at 7 time points: before breakfast, 90 minutes after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 minutes after start of dinner and at bedtime. Change from baseline (week 0) to week 54 and week 80 in 7-point SMPG postprandial glucose /prandial increment (breakfast, lunch and dinner) value are presented.
| mmol/L | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Change from week 0 to week 54: Breakfast | 1.3 ± 4.0 | 0.4 ± 3.0 | -0.1 ± 3.8 | -0.6 ± 2.4 |
| Change from week 0 to week 80: Breakfast | 1.9 ± 4.2 | 0.5 ± 4.0 | -0.1 ± 4.5 | -0.5 ± 4.5 |
| Change from week 0 to week 54: Lunch | 0.9 ± 4.5 | 0.5 ± 3.4 | 1.5 ± 2.9 | 0.7 ± 2.7 |
| Change from week 0 to week 80: Lunch | 0.0 ± 4.5 | 0.1 ± 3.0 | 1.0 ± 3.5 | 0.8 ± 4.5 |
| Change from week 0 to week 54: Dinner | 0.1 ± 4.5 | 1.1 ± 4.0 | -0.8 ± 4.7 | -0.3 ± 3.1 |
| Change from week 0 to week 80: Dinner | 0.5 ± 5.0 | 0.5 ± 3.4 | -0.4 ± 4.3 | -0.4 ± 3.2 |
Participants measured plasma glucose values using the blood glucose meter at 7 time points: before breakfast, 90 minutes after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 minutes after start of dinner, bedtime. Change from baseline (week 0) to week 54 and week 80 in 7-point self-measured plasma glucose (SMPG) postprandial glucose /prandial increment (average over the three meals) value is presented.
| mmol/L | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Change from week 0 to week 54 | 0.9 ± 2.3 | 0.6 ± 2.2 | 0.2 ± 2.0 | -0.1 ± 2.0 |
| Change from week 0 to week 80 | 0.8 ± 2.6 | 0.4 ± 2.2 | 0.0 ± 2.5 | -0.0 ± 2.9 |
Participants measured plasma glucose values using the blood glucose meter at 7 time points: before breakfast, 90 minutes after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 minutes after start of dinner, bedtime. Change from baseline (week 0) to week 54 and week 80 in mean of 7-point profiles value is presented.
| mmol/L | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Change from week 0 to week 54 | 0.5 ± 2.0 | 0.3 ± 2.4 | -0.1 ± 1.9 | 0.0 ± 1.2 |
| Change from week 0 to week 80 | 0.1 ± 2.1 | 0.0 ± 2.3 | 0.7 ± 1.6 | 0.3 ± 1.7 |
Participants measured plasma glucose values using the blood glucose meter at 7 time points: before breakfast, 90 minutes after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 minutes after start of dinner and at bedtime. Before breakfast 7-point self-measured plasma glucose (SMPG) profile values are presented at week 54 and week 80.
| mmol/L | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Week 54 | 6.8 ± 3.4 | 6.8 ± 2.7 | 6.4 ± 2.2 | 6.3 ± 1.4 |
| Week 80 | 6.5 ± 1.7 | 6.4 ± 2.0 | 7.2 ± 2.7 | 6.8 ± 2.0 |
AUCtau, NNC0114-0006 was derived as the area under the concentration-time curve using the linear trapezoidal technique based on observed values and actual measurement times between 0 and 6 weeks (after the last dose). This outcome measure was applicable for NNC0114-0006 + Liraglutide and NNC0114-0006 treatment arms.
| day*microgram per milliliter (day*ug/mL) | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) |
|---|---|---|
| Area Under the NNC0114-0006 Concentration-time Curve Over a Dosing Interval at Steady State (AUCtau, NNC0114-0006) | 3969 ± 17.9 | 4115 ± 23.1 |
Terminal half life was calculated as log(2)/λz. The terminal rate constant λz was determined through linear regression with the logarithm to concentration as the response variable and actual measurement time as the explanatory variable. Valid observations from the terminal part of the curve, which is approximately linear, were used for the determination. This outcome measure was applicable for NNC0114-0006 + Liraglutide and NNC0114-0006 treatment arms.
| Days | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) |
|---|---|---|
| Terminal Half-life (t½) After Last Dose of NNC0114-0006 | 22.3 ± 17.9 | 22.2 ± 16.5 |
The apparent volume of distribution of NNC0114-0006 at steady-state was calculated as mean residence time of (MRT) of NNC0114-0006 multiplied by clearance of NNC0114-0006 at steady state. This outcome measure was applicable for NNC0114-0006 + Liraglutide and NNC0114-0006 treatment arms.
| Milliliters per kilogram (mL/kg) | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) |
|---|---|---|
| Apparent Volume of Distribution of NNC0114-0006 at Steadystate (Vss, NNC0114-0006) | 83.7 ± 23.1 | 79.3 ± 17.6 |
Clearance of NNC0114-0006 at steady state was calculated as dose/AUCtau, NNC0114-0006. This outcome measure was applicable for NNC0114-0006 + Liraglutide and NNC0114-0006 treatment arms.
| (Milliliters/day)/kilogram ([mL/day]/kg) | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) |
|---|---|---|
| Clearance of NNC0114-0006 at Steady State (CLss, NNC0114-0006) | 3.02 ± 17.9 | 2.92 ± 23.1 |
This outcome measure was applicable for NNC0114-0006 + Liraglutide and NNC0114-0006 treatment arms. Mean residence time of NNC0114-0006 is presented.
| Days | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) |
|---|---|---|
| Mean Residence Time of NNC0114-0006 (MRT, NNC0114-0006) | 27.7 ± 24.5 | 27.2 ± 22.6 |
Accumulation ratio of NNC114-0006 was defined as AUC48-54 weeks/AUC0-6 weeks. This outcome measure was applicable for NNC0114-0006 + Liraglutide and NNC0114-0006 treatment arms.
| Ratio of AUC | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) |
|---|---|---|
| Accumulation Ratio of NNC114-0006 (RA,AUC, NNC0114-0006) | 1.24 ± 17.8 | 1.26 ± 17.4 |
Ctrough of NNC0114-0006 was defined as concentration prior to dosing of NNC0114-0006 at steady state. This outcome measure was applicable for NNC0114-0006 + Liraglutide and NNC0114-0006 treatment arms.
| microgram/milliliter (ug/mL) | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) |
|---|---|---|
| Observed NNC0114-0006 Concentration Prior to Dosing of NNC0114-0006 at Steady State (Ctrough, NNC0114-0006) | 34.7 ± 42.3 | 36.7 ± 36.8 |
C1h, NNC0114-0006 was defined as concentration of NNC0114-0006 at 1 hour after dosing of NNC0114-0006 at steady state. This outcome measure was applicable for NNC0114-0006 + Liraglutide and NNC0114-0006 treatment arms.
| ug/mL | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) |
|---|---|---|
| Observed NNC0114-0006 Concentration 1 Hour After Dosing of NNC0114-0006 at Steady State (C1h, NNC0114-0006) | 298.6 ± 16.8 | 282.6 ± 56.4 |
C liraglutide was defined as the liraglutide concentration at steady state. This outcome measure was applicable for NNC0114-0006 + Liraglutide and Liraglutide treatment arms.
| picomole per liter (pmol/L) | NNC0114-0006 + Liraglutide (Experimental) | Liraglutide (Experimental) |
|---|---|---|
| Liraglutide Concentration at Steady State (C Liraglutide) | 16287 ± 41.7 | 15920 ± 66.0 |
B cell panel is evaluated by Immune phenotyping of peripheral blood mononuclear cells (PBMC) at baseline (week 0), week 54 and week 80. In below table CD refer to Cluster of Differentiation; IgMNeg refers to Immunoglobulin M negative; IgDNeg refers to Immunoglobulin D negative.
| Percentage of B cells (%) | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Week 0: Activated Memory B-Cells | 1.3 ± 0.9 | 1.4 ± 1.0 | 1.6 ± 1.1 | 1.5 ± 1.0 |
| Week 54: Activated Memory B-Cells | 1.2 ± 0.8 | 1.1 ± 1.0 | 1.5 ± 1.3 | 1.3 ± 0.8 |
| Week 80: Activated Memory B-Cells | 1.2 ± 0.9 | 1.1 ± 0.7 | 1.5 ± 1.1 | 1.5 ± 1.2 |
| Week 0: Mature Naive B-Cells | 15.1 ± 6.7 | 14.0 ± 7.1 | 13.6 ± 6.9 | 13.3 ± 7.4 |
| Week 54: Mature Naive B-Cells | 14.0 ± 6.2 | 14.3 ± 7.9 | 13.6 ± 7.6 | 13.5 ± 6.9 |
| Week 80: Mature Naive B-Cells | 14.3 ± 7.3 | 14.2 ± 8.7 | 12.0 ± 5.2 | 12.8 ± 7.6 |
| Week 0: Antibody-Secreting Cells | 0.6 ± 0.4 | 0.5 ± 0.5 | 0.6 ± 0.3 | 0.6 ± 0.6 |
| Week 54: Antibody-Secreting Cells | 0.6 ± 0.5 | 0.4 ± 0.4 | 0.5 ± 0.3 | 0.6 ± 0.7 |
| Week 80: Antibody-Secreting Cells | 0.5 ± 0.4 | 0.4 ± 0.3 | 0.4 ± 0.4 | 0.6 ± 0.5 |
| Week 0: B-Cells Positive For Both CD19 & CD20 | 71.9 ± 9.7 | 71.1 ± 11.1 | 72.1 ± 8.9 | 72.2 ± 8.8 |
| Week 54: B-Cells Positive For Both CD19 & CD20 | 71.1 ± 12.4 | 70.8 ± 12.4 | 72.1 ± 8.4 | 65.9 ± 13.6 |
| Week 80: B-Cells Positive For Both CD19 & CD20 | 71.0 ± 10.7 | 69.8 ± 11.2 | 72.8 ± 10.6 | 69.6 ± 13.5 |
| Week 0: CD20Neg B-Cell | 0.6 ± 0.5 | 0.6 ± 0.7 | 0.6 ± 0.7 | 0.6 ± 0.5 |
| Week 54: CD20Neg B-Cell | 0.6 ± 0.7 | 0.5 ± 0.9 | 0.5 ± 0.4 | 0.6 ± 0.7 |
| Week 80: CD20Neg B-Cell | 0.5 ± 0.3 | 0.5 ± 0.4 | 0.6 ± 1.8 | 0.7 ± 1.0 |
| Week 0: CD24- B-Cells | 29.8 ± 10.2 | 31.0 ± 11.5 | 31.5 ± 11.8 | 32.0 ± 11.1 |
| Week 54: CD24- B-Cells | 30.2 ± 9.4 | 30.6 ± 10.8 | 31.3 ± 11.9 | 28.3 ± 8.9 |
| Week 80: CD24- B-Cells | 30.0 ± 8.9 | 31.6 ± 10.9 | 33.4 ± 12.4 | 30.7 ± 11.8 |
| Week 0: Class-Switched Memory B Cells | 5.0 ± 3.3 | 4.6 ± 2.5 | 4.8 ± 3.3 | 4.9 ± 3.0 |
| Week 54: Class-Switched Memory B Cells | 5.0 ± 3.7 | 4.2 ± 2.3 | 4.6 ± 2.9 | 4.8 ± 2.9 |
| Week 80: Class-Switched Memory B Cells | 4.6 ± 3.3 | 3.6 ± 2.0 | 4.6 ± 3.0 | 4.5 ± 2.5 |
| Week 0: IgMNeg IgDNeg Switched Memory B-cells | 0.1 ± 0.1 | 0.1 ± 0.1 | 0.1 ± 0.1 | 0.1 ± 0.1 |
| Week 54: IgMNeg IgDNeg Switched Memory B-cells | 0.1 ± 0.1 | 0.1 ± 0.1 | 0.1 ± 0.2 | 0.1 ± 0.1 |
| Week 80: IgMNeg IgDNeg Switched Memory B-cells | 0.1 ± 0.1 | 0.2 ± 0.2 | 0.1 ± 0.1 | 0.1 ± 0.1 |
| Week 0: Non-Class Switched Memory B-Cells | 10.2 ± 6.4 | 9.6 ± 5.8 | 9.6 ± 5.8 | 10.1 ± 6.4 |
| Week 54: Non-Class Switched Memory B-Cells | 8.5 ± 4.8 | 9.0 ± 5.7 | 8.7 ± 5.8 | 8.9 ± 5.8 |
| Week 80: Non-Class Switched Memory B-Cells | 8.2 ± 4.9 | 7.2 ± 4.1 | 8.0 ± 5.1 | 8.9 ± 6.2 |
| Week 0: Total B-Cell Population | 72.5 ± 9.8 | 71.7 ± 11.2 | 72.7 ± 9.0 | 72.8 ± 8.6 |
| Week 54: Total B-Cell Population | 71.7 ± 12.1 | 71.3 ± 11.9 | 72.6 ± 8.4 | 66.5 ± 13.3 |
| Week 80: Total B-Cell Population | 71.4 ± 10.7 | 70.3 ± 11.2 | 73.5 ± 9.6 | 70.4 ± 13.0 |
| Week 0: Transitional B-Cells | 11.4 ± 6.1 | 9.9 ± 6.5 | 9.5 ± 5.5 | 9.6 ± 6.6 |
| Week 54: Transitional B-Cells | 10.2 ± 5.6 | 10.7 ± 7.7 | 9.5 ± 6.3 | 9.8 ± 6.4 |
| Week 80: Transitional B-Cells | 10.8 ± 6.8 | 10.5 ± 8.1 | 8.1 ± 4.0 | 8.9 ± 6.1 |
NK cell panel is evaluated by Immune phenotyping of peripheral blood mononuclear cells (PBMC) at baseline (week 0), week 54 and week 80. In below table ADCC refer to Antibody-dependent cellular cytotoxicity; CD refer to Cluster of Differentiation.
| Percentage of NK cells (%) | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Week 0: ADCC-Competent NK | 39.5 ± 17.1 | 36.3 ± 14.9 | 36.0 ± 16.6 | 34.7 ± 14.6 |
| Week 54: ADCC-Competent NK | 37.1 ± 16.1 | 32.5 ± 14.1 | 33.9 ± 14.0 | 31.5 ± 14.0 |
| Week 80: ADCC-Competent NK | 37.1 ± 16.0 | 33.2 ± 13.7 | 31.9 ± 15.1 | 34.1 ± 16.3 |
| Week 0: CD16+ Highly Functional NK Cells | 0.8 ± 0.8 | 0.8 ± 0.7 | 0.7 ± 0.6 | 0.7 ± 0.6 |
| Week 54: CD16+ Highly Functional NK Cells | 0.7 ± 0.7 | 0.7 ± 0.8 | 0.7 ± 0.7 | 0.6 ± 0.5 |
| Week 80: CD16+ Highly Functional NK Cells | 0.7 ± 0.8 | 0.6 ± 0.5 | 0.6 ± 0.6 | 0.8 ± 0.7 |
| Week 0: CD56- Cells | 34.5 ± 15.9 | 36.8 ± 15.5 | 38.0 ± 17.1 | 38.0 ± 13.6 |
| Week 54: CD56- Cells | 34.8 ± 12.8 | 36.6 ± 12.9 | 38.1 ± 14.3 | 41.1 ± 15.7 |
| Week 80: CD56- Cells | 36.2 ± 14.3 | 37.6 ± 13.7 | 37.1 ± 11.7 | 37.6 ± 12.7 |
| Week 0: CD56High NK Pool | 4.9 ± 3.3 | 5.1 ± 3.5 | 4.5 ± 2.9 | 4.9 ± 3.7 |
| Week 54: CD56High NK Pool | 4.9 ± 3.1 | 5.3 ± 3.4 | 4.2 ± 2.9 | 4.4 ± 3.0 |
| Week 80: CD56High NK Pool | 4.5 ± 2.9 | 5.1 ± 3.1 | 4.3 ± 2.8 | 5.4 ± 4.0 |
| Week 0: CD57+ MatNK Effectors | 22.6 ± 12.5 | 20.4 ± 10.3 | 21.0 ± 11.8 | 19.0 ± 10.1 |
| Week 54: CD57+ MatNK Effectors | 21.0 ± 12.5 | 18.0 ± 10.1 | 18.9 ± 10.6 | 16.6 ± 9.4 |
| Week 80: CD57+ MatNK Effectors | 20.0 ± 11.2 | 18.3 ± 9.0 | 17.5 ± 11.1 | 17.3 ± 9.6 |
| Week 0: Functional NK Cells; Efficient At ADCC | 14.5 ± 7.8 | 13.3 ± 8.5 | 13.1 ± 9.7 | 12.1 ± 6.4 |
| Week 54: Functional NK Cells; Efficient At ADCC | 13.2 ± 8.5 | 11.1 ± 7.2 | 12.1 ± 7.1 | 11.0 ± 7.2 |
| Week 80: Functional NK Cells; Efficient At ADCC | 13.3 ± 7.4 | 11.3 ± 7.1 | 10.9 ± 7.2 | 12.6 ± 9.4 |
| Week 0: Highly Cytolytic Subset Of NK Cells | 18.8 ± 10.4 | 20.9 ± 10.3 | 20.6 ± 11.0 | 21.4 ± 9.4 |
| Week 54: Highly Cytolytic Subset Of NK Cells | 22.2 ± 10.7 | 24.5 ± 11.0 | 22.8 ± 11.5 | 22.1 ± 11.0 |
| Week 80: Highly Cytolytic Subset Of NK Cells | 21.1 ± 9.7 | 23.0 ± 9.1 | 25.5 ± 11.4 | 21.9 ± 9.9 |
| Week 0: Mature CD16+ Highly Functional NK Cells | 0.7 ± 0.7 | 0.7 ± 0.6 | 0.6 ± 0.6 | 0.7 ± 0.6 |
| Week 54: Mature CD16+ Highly Functional NK Cells | 0.6 ± 0.6 | 0.6 ± 0.8 | 0.6 ± 0.7 | 0.6 ± 0.5 |
| Week 80: Mature CD16+ Highly Functional NK Cells | 0.6 ± 0.7 | 0.6 ± 0.5 | 0.5 ± 0.6 | 0.7 ± 0.7 |
| Week 0: Mature CD16+ Terminally Differentiated | 1.3 ± 1.3 | 1.1 ± 1.2 | 1.1 ± 1.1 | 1.3 ± 1.1 |
| Week 54: Mature CD16+ Terminally Differentiated | 0.9 ± 0.7 | 0.8 ± 0.7 | 1.0 ± 0.9 | 1.1 ± 0.9 |
| Week 80: Mature CD16+ Terminally Differentiated | 1.1 ± 1.1 | 1.0 ± 1.0 | 0.8 ± 0.9 | 1.3 ± 1.0 |
| Week 0: Mature CD16- Terminally Differentiate NK | 0.3 ± 0.2 | 0.3 ± 0.2 | 0.4 ± 0.4 | 0.4 ± 0.3 |
| Week 54: Mature CD16- Terminally Differentiate NK | 0.3 ± 0.2 | 0.3 ± 0.2 | 0.3 ± 0.3 | 0.4 ± 0.2 |
| Week 80: Mature CD16- Terminally Differentiate NK | 0.3 ± 0.2 | 0.3 ± 0.3 | 0.4 ± 0.3 | 1.0 ± 4.2 |
| Week 0: Mature Cytolytic NK Cells | 2.3 ± 1.4 | 2.2 ± 1.1 | 2.4 ± 1.7 | 2.3 ± 1.3 |
| Week 54: Mature Cytolytic NK Cells | 2.4 ± 1.4 | 2.7 ± 1.5 | 2.5 ± 1.6 | 2.4 ± 1.7 |
| Week 80: Mature Cytolytic NK Cells | 2.3 ± 1.2 | 2.9 ± 3.7 | 2.6 ± 2.3 | 2.5 ± 1.5 |
| Week 0: Mature Rapid Cytokine-Producing NK Cell | 3.6 ± 2.5 | 3.8 ± 2.8 | 3.3 ± 2.2 | 3.6 ± 2.8 |
| Week 54: Mature Rapid Cytokine-Producing NK Cell | 3.6 ± 2.4 | 3.9 ± 2.4 | 3.0 ± 2.0 | 3.3 ± 2.4 |
| Week 80: Mature Rapid Cytokine-Producing NK Cell | 3.2 ± 2.0 | 3.7 ± 2.4 | 3.0 ± 1.9 | 3.9 ± 3.0 |
| Week 0: Rapid Cytokine-Producing NK Cell Subset | 4.1 ± 2.7 | 4.4 ± 3.1 | 3.8 ± 2.6 | 4.1 ± 3.2 |
| Week 54: Rapid Cytokine-Producing NK Cell Subset | 4.2 ± 2.7 | 4.5 ± 2.8 | 3.5 ± 2.3 | 3.8 ± 2.6 |
| Week 80: Rapid Cytokine-Producing NK Cell Subset | 3.8 ± 2.3 | 4.4 ± 2.7 | 3.7 ± 2.3 | 4.6 ± 3.4 |
| Week 0: Senescent CD16+ CD56- NK cells | 1.3 ± 1.8 | 1.2 ± 1.9 | 1.0 ± 1.1 | 1.2 ± 1.2 |
| Week 54: Senescent CD16+ CD56- NK cells | 1.0 ± 1.1 | 1.2 ± 1.5 | 0.9 ± 0.9 | 1.1 ± 1.1 |
| Week 80: Senescent CD16+ CD56- NK cells | 1.1 ± 1.4 | 1.4 ± 1.5 | 0.9 ± 0.9 | 1.2 ± 1.0 |
| Week 0: Senescent CD16+CD56hi NK | 0.1 ± 0.2 | 0.1 ± 0.1 | 0.1 ± 0.1 | 0.1 ± 0.1 |
| Week 54: Week 0: Senescent CD16+CD56hi NK | 0.1 ± 0.1 | 0.0 ± 0.1 | 0.1 ± 0.1 | 0.0 ± 0.1 |
| Week 80: Week 0: Senescent CD16+CD56hi NK | 0.1 ± 0.1 | 0.0 ± 0.0 | 0.1 ± 0.1 | 0.1 ± 0.1 |
| Week 0: Senescent CD16- CD56- NK cells | 1.3 ± 1.0 | 1.5 ± 1.6 | 1.3 ± 1.0 | 1.5 ± 1.1 |
| Week 54: Senescent CD16- CD56- NK cells | 1.5 ± 1.2 | 1.8 ± 1.3 | 1.6 ± 1.3 | 2.0 ± 2.9 |
| Week 80: Senescent CD16- CD56- NK cells | 1.9 ± 2.0 | 2.4 ± 3.7 | 1.9 ± 1.3 | 2.2 ± 3.3 |
| Week 0: Senescent Cytolytic NK Cells | 8.7 ± 6.6 | 9.9 ± 7.2 | 9.8 ± 7.2 | 9.9 ± 6.0 |
| Week 54: Senescent Cytolytic NK Cells | 9.9 ± 6.3 | 11.3 ± 7.6 | 10.9 ± 7.9 | 9.6 ± 6.7 |
| Week 80: Senescent Cytolytic NK Cells | 9.4 ± 6.1 | 11.1 ± 7.1 | 11.5 ± 7.9 | 9.8 ± 7.3 |
| Week 0: Senescent Rapid Cytokine-Producing NK | 0.1 ± 0.3 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.0 |
| Week 54: Senescent Rapid Cytokine-Producing NK | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.1 | 0.0 ± 0.0 |
| Week 80: Senescent Rapid Cytokine-Producing NK | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.1 |
| Week 0: Total CD16+ CD56- NK | 6.7 ± 3.8 | 7.4 ± 5.1 | 6.4 ± 3.5 | 7.3 ± 3.8 |
| Week 54: Total CD16+ CD56- NK | 5.9 ± 2.6 | 6.2 ± 3.8 | 6.0 ± 3.1 | 6.8 ± 3.5 |
| Week 80: Total CD16+ CD56- NK | 6.8 ± 5.8 | 6.6 ± 4.1 | 6.2 ± 3.0 | 7.3 ± 3.5 |
| Week 0: Total CD16- CD56- NK | 27.6 ± 15.4 | 29.2 ± 13.2 | 31.4 ± 16.7 | 30.5 ± 13.0 |
| Week 54: Week 0: Total CD16- CD56- NK | 28.6 ± 12.2 | 30.1 ± 11.9 | 31.9 ± 13.3 | 34.0 ± 14.1 |
| Week 80: Week 0: Total CD16- CD56- NK | 29.2 ± 12.7 | 30.7 ± 13.2 | 30.7 ± 10.2 | 30.0 ± 12.2 |
| Week 0: Total Mature NK Cells; Highly Cytolytic | 58.6 ± 13.4 | 57.4 ± 15.1 | 56.8 ± 16.6 | 56.3 ± 13.7 |
| Week 54: Total Mature NK Cells; Highly Cytolytic | 59.6 ± 13.4 | 57.3 ± 12.9 | 56.9 ± 13.8 | 53.7 ± 15.0 |
| Week 80: Total Mature NK Cells; Highly Cytolytic | 58.5 ± 13.9 | 56.5 ± 13.4 | 57.7 ± 12.1 | 56.2 ± 11.6 |
T cell panel is evaluated by Immune phenotyping of peripheral blood mononuclear cells (PBMC) at baseline (week 0), week 54 and week 80. In below table CD refer to Cluster of Differentiation; TEMRA refers to terminally differentiated effector memory cells re-expressing CD45RA; CCR refers to C-C chemokine receptor; TREG refers to Regulatory T cells.
| Percentage of T cells (%) | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Week 0: Activated CD4 TEMRA | 10.1 ± 7.1 | 9.7 ± 5.4 | 10.8 ± 6.8 | 9.7 ± 6.5 |
| Week 54: Activated CD4 TEMRA | 10.3 ± 5.9 | 8.7 ± 5.3 | 9.7 ± 5.4 | 9.3 ± 6.0 |
| Week 80: Activated CD4 TEMRA | 9.1 ± 5.5 | 8.1 ± 5.5 | 8.1 ± 4.9 | 8.7 ± 5.0 |
| Week 0: Activated CD8 TEMRA | 0.9 ± 1.2 | 0.8 ± 1.4 | 0.6 ± 0.6 | 1.0 ± 1.9 |
| Week 54: Activated CD8 TEMRA | 0.9 ± 1.5 | 0.6 ± 0.7 | 0.6 ± 0.6 | 0.7 ± 1.0 |
| Week 80: Activated CD8 TEMRA | 0.7 ± 0.9 | 0.6 ± 0.7 | 0.6 ± 0.6 | 1.1 ± 2.3 |
| Week 0: Activated Central Memory CD4 | 6.3 ± 3.3 | 6.7 ± 3.1 | 7.1 ± 3.8 | 6.1 ± 3.2 |
| Week 54: Activated Central Memory CD4 | 6.3 ± 3.1 | 6.1 ± 3.1 | 6.3 ± 2.9 | 6.2 ± 3.1 |
| Week 80: Activated Central Memory CD4 | 6.5 ± 3.0 | 6.0 ± 2.6 | 6.0 ± 2.6 | 6.5 ± 2.8 |
| Week 0: Activated Central Memory CD8 | 1.1 ± 1.2 | 1.7 ± 1.8 | 1.6 ± 1.7 | 1.1 ± 1.0 |
| Week 54: Activated Central Memory CD8 | 1.4 ± 1.6 | 1.6 ± 1.8 | 1.5 ± 1.4 | 3.1 ± 13.3 |
| Week 80: Activated Central Memory CD8 | 2.2 ± 6.5 | 1.4 ± 1.5 | 1.6 ± 2.3 | 1.9 ± 4.5 |
| Week 0: Activated Effector Memory CD4 | 10.3 ± 5.8 | 10.9 ± 5.6 | 11.3 ± 6.4 | 9.4 ± 4.8 |
| Week 54: Activated Effector Memory CD4 | 10.1 ± 5.4 | 9.6 ± 5.2 | 10.0 ± 4.9 | 9.2 ± 4.8 |
| Week 80: Activated Effector Memory CD4 | 10.2 ± 6.6 | 8.9 ± 4.3 | 9.5 ± 4.8 | 9.1 ± 4.3 |
| Week 0: Activated Effector Memory CD8 | 1.9 ± 3.6 | 1.7 ± 2.9 | 1.2 ± 1.4 | 0.9 ± 1.2 |
| Week 54: Activated Effector Memory CD8 | 2.0 ± 3.7 | 1.6 ± 2.4 | 1.2 ± 1.2 | 1.1 ± 1.4 |
| Week 80: Activated Effector Memory CD8 | 1.9 ± 3.4 | 1.5 ± 2.8 | 1.4 ± 2.0 | 1.1 ± 1.4 |
| Week 0: Activated Mature Naive CD4 T-Cells | 4.0 ± 2.0 | 4.0 ± 1.9 | 4.7 ± 2.4 | 3.9 ± 1.8 |
| Week 54: Activated Mature Naive CD4 T-Cells | 3.9 ± 2.1 | 3.8 ± 1.8 | 4.5 ± 2.3 | 3.7 ± 1.4 |
| Week 80: Activated Mature Naive CD4 T-Cells | 4.0 ± 2.4 | 3.8 ± 1.4 | 4.0 ± 1.9 | 3.9 ± 1.7 |
| Week 0: Activated Mature Naive CD8 T-Cells | 3.4 ± 3.7 | 2.8 ± 2.3 | 3.3 ± 3.5 | 3.5 ± 3.7 |
| Week 54: Activated Mature Naive CD8 T-Cells | 3.0 ± 3.3 | 2.6 ± 3.0 | 2.6 ± 2.7 | 3.1 ± 3.6 |
| Week 80: Activated Mature Naive CD8 T-Cells | 2.7 ± 2.1 | 2.6 ± 2.5 | 2.5 ± 2.7 | 3.1 ± 3.2 |
| Week 0: CCR5+ CD4 TEMRA | 17.7 ± 12.2 | 16.4 ± 8.1 | 16.9 ± 11.1 | 18.9 ± 12.8 |
| Week 54: CCR5+ CD4 TEMRA | 18.4 ± 12.2 | 17.7 ± 10.3 | 18.8 ± 13.5 | 21.0 ± 17.3 |
| Week 80: CCR5+ CD4 TEMRA | 18.3 ± 11.0 | 19.5 ± 13.6 | 18.6 ± 11.9 | 21.4 ± 15.1 |
| Week 0: CCR5+ CD4 Treg TEMRA | 3.7 ± 10.6 | 1.7 ± 1.8 | 2.7 ± 4.7 | 3.9 ± 8.6 |
| Week 54: CCR5+ CD4 Treg TEMRA | 4.2 ± 9.1 | 4.2 ± 10.4 | 4.6 ± 10.5 | 4.6 ± 9.3 |
| Week 80: CCR5+ CD4 Treg TEMRA | 2.8 ± 4.6 | 4.4 ± 10.4 | 3.2 ± 5.7 | 4.4 ± 9.3 |
| Week 0: CCR5+ CD8 EM | 35.3 ± 14.5 | 35.5 ± 13.8 | 38.2 ± 14.1 | 37.7 ± 15.8 |
| Week 54: CCR5+ CD8 EM | 37.9 ± 14.1 | 36.4 ± 13.5 | 38.0 ± 14.4 | 38.8 ± 15.5 |
| Week 80: CCR5+ CD8 EM | 38.8 ± 15.3 | 34.7 ± 12.4 | 37.5 ± 14.1 | 40.0 ± 16.3 |
| Week 0: CCR5+ CD8 TEMRA | 22.8 ± 10.2 | 22.9 ± 10.9 | 25.9 ± 12.9 | 24.3 ± 12.6 |
| Week 54: CCR5+ CD8 TEMRA | 25.9 ± 10.7 | 25.0 ± 9.7 | 26.3 ± 12.1 | 25.4 ± 11.6 |
| Week 80: CCR5+ CD8 TEMRA | 25.9 ± 11.3 | 24.4 ± 11.3 | 26.8 ± 13.4 | 26.9 ± 13.1 |
| Week 0: CCR5+ Central Memory CD4 Cells | 4.1 ± 2.4 | 4.3 ± 2.3 | 4.5 ± 2.9 | 4.5 ± 3.2 |
| Week 54: CCR5+ Central Memory CD4 Cells | 4.5 ± 2.5 | 4.1 ± 2.0 | 4.1 ± 2.8 | 4.9 ± 3.4 |
| Week 80: CCR5+ Central Memory CD4 Cells | 4.9 ± 2.5 | 4.9 ± 3.7 | 5.1 ± 3.4 | 5.7 ± 4.7 |
| Week 0: CCR5+ Central Memory CD8 Cells | 15.0 ± 10.6 | 14.4 ± 9.0 | 16.9 ± 10.3 | 16.7 ± 11.1 |
| Week 54: CCR5+ Central Memory CD8 Cells | 16.8 ± 9.0 | 14.2 ± 9.7 | 15.8 ± 9.7 | 18.5 ± 15.6 |
| Week 80: CCR5+ Central Memory CD8 Cells | 16.8 ± 8.9 | 15.5 ± 8.9 | 15.8 ± 9.2 | 19.3 ± 13.5 |
| Week 0: CCR5+ Central Memory Regulatory T-Cells | 1.9 ± 1.7 | 1.8 ± 1.4 | 1.8 ± 1.9 | 1.5 ± 1.1 |
| Week 54: CCR5+ Central Memory Regulatory T-Cells | 2.0 ± 1.7 | 1.5 ± 1.3 | 1.7 ± 1.8 | 1.7 ± 1.3 |
| Week 80: CCR5+ Central Memory Regulatory T-Cells | 2.1 ± 1.9 | 1.8 ± 1.7 | 1.9 ± 1.9 | 2.2 ± 2.4 |
| Week 0: CCR5+ Effector Memory CD4 | 15.5 ± 7.9 | 14.5 ± 7.6 | 15.5 ± 8.3 | 15.3 ± 7.4 |
| Week 54: CCR5+ Effector Memory CD4 | 16.2 ± 7.7 | 15.7 ± 7.6 | 14.9 ± 7.5 | 16.9 ± 9.6 |
| Week 80: CCR5+ Effector Memory CD4 | 17.5 ± 7.5 | 16.8 ± 9.2 | 16.4 ± 8.0 | 18.4 ± 10.9 |
| Week 0: CCR5+ Effector Memory Regulatory T-Cells | 4.7 ± 3.5 | 5.1 ± 3.3 | 4.5 ± 3.9 | 4.1 ± 2.3 |
| Week 54: CCR5+ Effector Memory Regulatory T-Cells | 4.8 ± 3.0 | 4.6 ± 3.1 | 4.4 ± 3.3 | 4.5 ± 2.5 |
| Week 80: CCR5+ Effector Memory Regulatory T-Cells | 5.2 ± 3.6 | 5.2 ± 4.0 | 5.4 ± 5.3 | 5.2 ± 3.2 |
| Week 0: CCR5+ Naive CD4 T-Cells | 1.9 ± 1.5 | 2.0 ± 1.3 | 2.1 ± 1.9 | 2.0 ± 1.8 |
| Week 54: CCR5+ Naive CD4 T-Cells | 2.0 ± 1.5 | 2.1 ± 2.1 | 2.1 ± 1.9 | 2.3 ± 2.2 |
| Week 80: CCR5+ Naive CD4 T-Cells | 2.3 ± 1.6 | 2.9 ± 3.9 | 2.8 ± 3.0 | 3.5 ± 5.1 |
| Week 0: CCR5+ Naive CD8 T-Cells | 3.7 ± 2.3 | 3.5 ± 1.9 | 4.1 ± 2.8 | 4.2 ± 3.2 |
| Week 54: CCR5+ Naive CD8 T-Cells | 3.4 ± 1.7 | 3.5 ± 2.4 | 3.5 ± 2.1 | 4.1 ± 2.9 |
| Week 80: CCR5+ Naive CD8 T-Cells | 3.8 ± 1.8 | 4.0 ± 4.3 | 4.3 ± 3.1 | 4.9 ± 4.7 |
| Week 0: CCR5+ Naive Regulatory T-Cells | 6.1 ± 6.5 | 5.0 ± 3.6 | 6.5 ± 8.3 | 6.5 ± 8.8 |
| Week 54: CCR5+ Naive Regulatory T-Cells | 6.7 ± 10.1 | 6.3 ± 7.3 | 4.8 ± 5.5 | 5.3 ± 5.2 |
| Week 80: CCR5+ Naive Regulatory T-Cells | 5.8 ± 4.9 | 6.5 ± 8.4 | 5.7 ± 6.5 | 7.1 ± 8.0 |
| Week 0: CD4 TEMRA | 3.7 ± 4.9 | 2.6 ± 1.7 | 3.1 ± 2.5 | 2.7 ± 2.3 |
| Week 54: CD4 TEMRA | 3.8 ± 5.7 | 2.9 ± 2.3 | 3.3 ± 2.8 | 3.1 ± 3.2 |
| Week 80: CD4 TEMRA | 4.4 ± 5.8 | 3.2 ± 2.3 | 3.6 ± 3.2 | 3.5 ± 2.6 |
| Week 0: CD8 Central Memory | 2.0 ± 1.8 | 2.0 ± 2.1 | 1.8 ± 1.5 | 1.9 ± 1.3 |
| Week 54: CD8 Central Memory | 1.8 ± 1.2 | 2.1 ± 2.3 | 1.7 ± 1.4 | 2.1 ± 1.6 |
| Week 80: CD8 Central Memory | 1.8 ± 1.6 | 1.9 ± 2.0 | 1.8 ± 1.5 | 2.2 ± 2.0 |
| Week 0: CD8 Effector Memory | 14.3 ± 7.9 | 14.7 ± 7.6 | 13.4 ± 7.7 | 15.7 ± 6.9 |
| Week 54: CD8 Effector Memory | 15.1 ± 7.6 | 14.8 ± 7.8 | 11.3 ± 6.6 | 16.4 ± 7.4 |
| Week 80: CD8 Effector Memory | 15.1 ± 8.0 | 16.5 ± 9.0 | 13.9 ± 7.6 | 17.4 ± 7.5 |
| Week 0: CD8 TEMRA | 31.6 ± 12.8 | 30.9 ± 13.9 | 29.0 ± 12.8 | 32.3 ± 13.8 |
| Week 54: CD8 TEMRA | 29.8 ± 12.3 | 31.0 ± 13.9 | 30.3 ± 12.9 | 30.4 ± 13.3 |
| Week 80: CD8 TEMRA | 31.9 ± 14.3 | 33.5 ± 13.1 | 30.4 ± 13.0 | 33.4 ± 14.6 |
| Week 0: Conventional Central Memory CD4 T-Cells | 20.0 ± 9.9 | 22.1 ± 8.0 | 20.3 ± 8.1 | 21.6 ± 8.0 |
| Week 54: Conventional Central Memory CD4 T-Cells | 20.4 ± 8.1 | 22.2 ± 9.3 | 19.9 ± 7.8 | 21.1 ± 8.0 |
| Week 80: Conventional Central Memory CD4 T-Cells | 19.4 ± 8.4 | 21.7 ± 7.8 | 19.9 ± 8.2 | 21.1 ± 8.7 |
| Week 0: Conventional Effector Memory CD4 T-Cells | 19.2 ± 10.7 | 22.8 ± 10.3 | 19.5 ± 9.5 | 20.7 ± 9.2 |
| Week 54: Conventional Effector Memory CD4 T-Cells | 20.3 ± 9.6 | 22.9 ± 11.0 | 20.5 ± 10.7 | 21.3 ± 9.7 |
| Week 80: Conventional Effector Memory CD4 T-Cells | 20.0 ± 9.8 | 24.4 ± 11.3 | 20.9 ± 11.7 | 23.2 ± 10.0 |
| Week 0: Naive CD4 T-Cells | 57.0 ± 14.7 | 52.4 ± 14.4 | 57.0 ± 12.6 | 54.9 ± 13.2 |
| Week 54: Naive CD4 T-Cells | 55.4 ± 11.9 | 51.8 ± 15.0 | 56.3 ± 13.9 | 54.5 ± 12.5 |
| Week 80: Naive CD4 T-Cells | 56.1 ± 11.9 | 50.6 ± 16.2 | 55.6 ± 15.1 | 52.1 ± 14.5 |
| Week 0: Naive CD8 T-Cells | 52.0 ± 15.9 | 52.5 ± 19.1 | 55.8 ± 17.0 | 50.1 ± 17.4 |
| Week 54: Naive CD8 T-Cells | 53.2 ± 14.9 | 52.1 ± 18.1 | 54.7 ± 15.4 | 51.1 ± 17.4 |
| Week 80: Naive CD8 T-Cells | 51.1 ± 16.0 | 48.1 ± 19.2 | 53.9 ± 17.4 | 46.9 ± 17.6 |
| Week 0: Senescent CD4 Central Memory Cells | 2.3 ± 1.9 | 2.2 ± 1.5 | 2.4 ± 2.6 | 2.3 ± 2.7 |
| Week 54: Senescent CD4 Central Memory Cells | 1.9 ± 1.5 | 2.1 ± 1.7 | 2.2 ± 1.9 | 2.4 ± 2.5 |
| Week 80: Senescent CD4 Central Memory Cells | 2.3 ± 1.8 | 2.3 ± 1.6 | 2.1 ± 1.6 | 2.6 ± 2.4 |
| Week 0: Senescent CD4 Effector Memory Cells | 6.9 ± 5.5 | 6.3 ± 5.6 | 6.9 ± 5.4 | 6.7 ± 6.5 |
| Week 54: Senescent CD4 Effector Memory Cells | 5.9 ± 5.8 | 6.7 ± 6.0 | 6.6 ± 4.9 | 7.5 ± 9.0 |
| Week 80: Senescent CD4 Effector Memory Cells | 6.9 ± 5.9 | 7.0 ± 5.2 | 6.4 ± 4.7 | 7.6 ± 7.4 |
| Week 0: Senescent CD8 Central Memory Cells | 12.1 ± 10.1 | 11.5 ± 9.1 | 12.9 ± 9.7 | 12.4 ± 12.7 |
| Week 54: Senescent CD8 Central Memory Cells | 11.7 ± 9.5 | 10.4 ± 9.2 | 12.0 ± 10.2 | 12.2 ± 14.5 |
| Week 80: Senescent CD8 Central Memory Cells | 12.7 ± 9.0 | 12.7 ± 9.9 | 11.3 ± 9.8 | 12.2 ± 11.9 |
| Week 0: Senescent CD8 Effector Memory Cells | 27.3 ± 14.8 | 27.2 ± 15.5 | 27.7 ± 13.6 | 29.1 ± 17.4 |
| Week 54: Senescent CD8 Effector Memory Cells | 25.2 ± 13.1 | 25.1 ± 14.3 | 26.1 ± 12.8 | 25.8 ± 14.7 |
| Week 80: Senescent CD8 Effector Memory Cells | 27.5 ± 14.5 | 28.6 ± 15.7 | 26.5 ± 14.1 | 26.6 ± 15.5 |
| Week 0: Senescent Naive CD4 T-Cells | 2.6 ± 2.7 | 2.9 ± 3.3 | 2.6 ± 2.3 | 2.5 ± 2.3 |
| Week 54: Senescent Naive CD4 T-Cells | 2.5 ± 2.5 | 3.0 ± 3.8 | 2.8 ± 3.0 | 2.7 ± 2.4 |
| Week 80: Senescent Naive CD4 T-Cells | 3.1 ± 3.3 | 3.3 ± 3.8 | 3.1 ± 3.7 | 3.9 ± 5.3 |
| Week 0: Senescent Naive CD8 T-Cells | 3.9 ± 3.4 | 3.6 ± 3.5 | 3.5 ± 3.1 | 4.2 ± 4.4 |
| Week 54: Senescent Naive CD8 T-Cells | 3.5 ± 2.9 | 3.8 ± 4.5 | 3.7 ± 4.3 | 4.2 ± 3.6 |
| Week 80: Senescent Naive CD8 T-Cells | 4.4 ± 4.3 | 4.3 ± 4.7 | 3.8 ± 3.6 | 4.5 ± 4.1 |
| Week 0: Senescent Naive TREG | 6.9 ± 7.9 | 5.5 ± 3.7 | 7.1 ± 8.5 | 7.3 ± 9.3 |
| Week 54: Senescent Naive TREG | 7.2 ± 10.9 | 6.8 ± 7.8 | 5.0 ± 5.5 | 5.6 ± 5.2 |
| Week 80: Senescent Naive TREG | 6.3 ± 5.7 | 7.0 ± 8.9 | 6.0 ± 7.2 | 7.4 ± 8.2 |
| Week 0: Senescent TEMRA CD4 | 23.3 ± 19.8 | 21.7 ± 18.4 | 21.9 ± 21.7 | 22.0 ± 20.1 |
| Week 54: Senescent TEMRA CD4 | 20.0 ± 17.1 | 22.8 ± 18.3 | 23.1 ± 22.2 | 23.5 ± 21.7 |
| Week 80: Senescent TEMRA CD4 | 21.0 ± 19.5 | 24.2 ± 18.1 | 21.7 ± 21.5 | 25.4 ± 21.6 |
| Week 0: Senescent TEMRA CD8 | 42.8 ± 20.2 | 40.3 ± 21.0 | 37.7 ± 19.4 | 42.0 ± 23.0 |
| Week 54: Senescent TEMRA CD8 | 39.2 ± 19.8 | 40.7 ± 21.3 | 38.3 ± 18.4 | 40.4 ± 22.9 |
| Week 80: Senescent TEMRA CD8 | 42.7 ± 21.4 | 44.8 ± 20.9 | 38.7 ± 20.4 | 43.5 ± 23.1 |
| Week 0: Senescent TEMRA TREG | 3.6 ± 19.7 | 1.8 ± 1.9 | 2.8 ± 4.6 | 4.0 ± 8.6 |
| Week 54: Senescent TEMRA TREG | 3.9 ± 9.0 | 4.2 ± 10.4 | 4.6 ± 10.5 | 4.6 ± 9.1 |
| Week 80: Senescent TEMRA TREG | 2.6 ± 4.5 | 4.4 ± 10.4 | 3.2 ± 5.7 | 4.4 ± 9.3 |
| Week 0: Senescent TREG CM | 0.1 ± 0.1 | 0.1 ± 0.1 | 0.1 ± 0.2 | 0.2 ± 0.2 |
| Week 54: Senescent TREG CM | 0.1 ± 0.1 | 0.1 ± 0.1 | 0.1 ± 0.2 | 0.2 ± 0.2 |
| Week 80: Senescent TREG CM | 0.2 ± 0.2 | 0.2 ± 0.1 | 0.1 ± 0.2 | 0.3 ± 0.5 |
| Week 0: Senescent TREG EM | 0.4 ± 0.4 | 0.4 ± 0.3 | 0.4 ± 0.5 | 0.4 ± 0.4 |
| Week 54: Senescent TREG EM | 0.4 ± 0.4 | 0.3 ± 0.3 | 0.3 ± 0.3 | 0.5 ± 0.5 |
| Week 80: Senescent TREG EM | 0.5 ± 0.7 | 0.5 ± 0.9 | 0.5 ± 0.7 | 0.5 ± 0.7 |
| Week 0: Total Naive TREG | 46.8 ± 18.1 | 42.4 ± 14.1 | 50.3 ± 14.2 | 47.7 ± 17.6 |
| Week 54: Total Naive TREG | 43.7 ± 15.6 | 44.3 ± 15.8 | 49.4 ± 15.4 | 45.1 ± 13.7 |
| Week 80: Total Naive TREG | 46.8 ± 15.7 | 44.1 ± 18.3 | 48.7 ± 17.0 | 43.4 ± 15.2 |
| Week 0: Total TREG | 3.9 ± 1.9 | 3.8 ± 1.5 | 4.1 ± 1.6 | 3.5 ± 1.3 |
| Week 54: Total TREG | 3.8 ± 1.5 | 3.5 ± 1.5 | 4.0 ± 1.5 | 3.5 ± 1.2 |
| Week 80: Total TREG | 3.7 ± 1.5 | 3.5 ± 1.3 | 3.4 ± 1.2 | 3.4 ± 1.2 |
| Week 0: Total TREG CM | 14.8 ± 9.2 | 15.8 ± 8.1 | 14.4 ± 7.9 | 14.2 ± 7.9 |
| Week 54: Total TREG CM | 15.5 ± 9.0 | 15.6 ± 9.5 | 13.8 ± 7.8 | 15.0 ± 6.7 |
| Week 80: Total TREG CM | 15.3 ± 8.7 | 15.0 ± 8.2 | 13.8 ± 7.4 | 15.9 ± 8.2 |
| Week 0: Total TREG EM | 30.8 ± 14.6 | 36.4 ± 11.2 | 28.8 ± 12.2 | 30.7 ± 15.2 |
| Week 54: Total TREG EM | 32.4 ± 14.6 | 32.6 ± 12.5 | 28.3 ± 12.9 | 31.9 ± 13.6 |
| Week 80: Total TREG EM | 30.7 ± 13.7 | 33.5 ± 13.9 | 30.2 ± 15.0 | 32.9 ± 13.3 |
| Week 0: Total TREG TEMRA | 7.6 ± 11.5 | 5.5 ± 3.5 | 6.7 ± 5.7 | 7.5 ± 9.0 |
| Week 54: Total TREG TEMRA | 8.5 ± 11.4 | 7.7 ± 10.5 | 8.6 ± 10.4 | 8.2 ± 10.3 |
| Week 80: Total TREG TEMRA | 7.3 ± 8.1 | 7.4 ± 10.3 | 7.5 ± 6.8 | 7.8 ± 9.3 |
| Week 0: Total Viable CD4 T-Cells | 54.7 ± 10.7 | 53.2 ± 8.7 | 54.6 ± 11.3 | 54.6 ± 11.5 |
| Week 54: Total Viable CD4 T-Cells | 54.3 ± 11.3 | 52.1 ± 12.2 | 54.6 ± 12.7 | 52.7 ± 12.7 |
| Week 80: Total Viable CD4 T-Cells | 51.9 ± 13.3 | 50.3 ± 13.8 | 53.1 ± 12.6 | 52.2 ± 13.5 |
| Week 0: Total Viable CD8 T-Cells | 26.1 ± 8.1 | 28.2 ± 8.7 | 25.8 ± 7.6 | 26.6 ± 8.3 |
| Week 54: Total Viable CD8 T-Cells | 25.0 ± 7.9 | 26.7 ± 9.4 | 24.6 ± 7.9 | 24.0 ± 9.8 |
| Week 80: Total Viable CD8 T-Cells | 24.2 ± 8.9 | 25.4 ± 9.5 | 23.5 ± 8.9 | 23.9 ± 9.7 |
| Week 0: Total Viable T-Cells | 55.6 ± 7.1 | 55.2 ± 8.1 | 55.3 ± 8.0 | 55.0 ± 7.2 |
| Week 54: Total Viable T-Cells | 53.6 ± 7.0 | 55.9 ± 6.7 | 57.4 ± 7.7 | 55.5 ± 8.7 |
| Week 80: Total Viable T-Cells | 52.7 ± 8.6 | 55.3 ± 7.9 | 56.2 ± 8.0 | 55.8 ± 7.9 |
TfH cell panel is evaluated by Immune phenotyping of peripheral blood mononuclear cells (PBMC) at baseline (week 0), week 54 and week 80. In below table CTFH refer to Circulating T follicular helper; ICOS refers to inducible T-cell co-stimulator; PD refers to Programmed cell death protein; CCR refers to C-C chemokine receptor; CXCR refers to C-X-C chemokine receptor; CD refer to Cluster of Differentiation; CM refers to central memory; EM refers to effector memory, TIGIT refers to T cell immunoreceptor with Ig and ITIM domains.
| Percentage of TfH cells (%) | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Week 0: Activated cTfh17 Cells | 0.8 ± 1.2 | 1.0 ± 2.2 | 0.8 ± 1.6 | 0.6 ± 0.9 |
| Week 54: Activated cTfh17 Cells | 0.6 ± 1.2 | 0.4 ± 0.8 | 0.7 ± 1.2 | 0.9 ± 2.0 |
| Week 80: Activated cTfh17 Cells | 0.8 ± 2.0 | 1.1 ± 2.9 | 0.6 ± 0.8 | 0.9 ± 1.4 |
| Week 0: Activated cTfh2 Cells | 0.6 ± 0.6 | 0.6 ± 0.6 | 0.6 ± 0.5 | 0.6 ± 0.6 |
| Week 54: Activated cTfh2 Cells | 0.4 ± 0.4 | 0.4 ± 0.4 | 0.7 ± 1.2 | 0.6 ± 0.6 |
| Week 80: Activated cTfh2 Cells | 0.6 ± 0.6 | 0.5 ± 0.3 | 0.5 ± 0.5 | 0.6 ± 0.6 |
| Week 0:Activated PD1+ICOS+ cTfh1 | 1.3 ± 1.7 | 1.9 ± 7.7 | 1.1 ± 1.2 | 1.0 ± 1.1 |
| Week 54: Activated PD1+ICOS+ cTfh1 | 0.7 ± 0.6 | 1.0 ± 1.2 | 1.2 ± 2.5 | 1.2 ± 1.4 |
| Week 80: Activated PD1+ICOS+ cTfh1 | 0.7 ± 0.6 | 0.9 ± 1.0 | 1.0 ± 2.1 | 1.1 ± 2.5 |
| Week 0: CCR7+ cTfh1 Cells | 96.9 ± 2.5 | 97.1 ± 3.5 | 94.7 ± 13.4 | 97.2 ± 2.2 |
| Week 54: CCR7+ cTfh1 Cells | 97.1 ± 2.5 | 95.8 ± 13.1 | 97.1 ± 4.2 | 97.3 ± 2.3 |
| Week 80: CCR7+ cTfh1 Cells | 97.0 ± 3.0 | 96.8 ± 3.0 | 97.4 ± 2.1 | 97.0 ± 2.3 |
| Week 0: CCR7+ cTfh17 Cells | 97.4 ± 11.7 | 97.4 ± 11.9 | 97.4 ± 12.5 | 97.3 ± 11.8 |
| Week 54: CCR7+ cTfh17 Cells | 98.1 ± 2.9 | 93.9 ± 22.3 | 96.9 ± 12.9 | 95.3 ± 18.3 |
| Week 80: CCR7+ cTfh17 Cells | 98.7 ± 1.5 | 97.3 ± 5.9 | 96.8 ± 13.4 | 98.7 ± 1.4 |
| Week 0: CCR7+ cTfh2 Cells | 98.1 ± 1.6 | 98.2 ± 1.4 | 98.2 ± 1.5 | 98.3 ± 1.4 |
| Week 54: CCR7+ cTfh2 Cells | 98.1 ± 1.9 | 98.5 ± 1.2 | 98.3 ± 1.1 | 98.1 ± 1.6 |
| Week 80: CCR7+ cTfh2 Cells | 98.3 ± 1.5 | 98.3 ± 1.8 | 98.4 ± 1.1 | 98.3 ± 1.0 |
| Week 0: CXCR4+ cTfh1 Cells | 59.4 ± 27.6 | 58.0 ± 25.9 | 54.9 ± 27.8 | 55.6 ± 29.2 |
| Week 54: CXCR4+ cTfh1 Cells | 64.5 ± 28.7 | 64.5 ± 28.8 | 64.4 ± 29.3 | 69.4 ± 25.0 |
| Week 80: CXCR4+ cTfh1 Cells | 70.8 ± 24.5 | 66.4 ± 27.4 | 63.5 ± 30.3 | 66.8 ± 25.2 |
| Week 0: CXCR4+ cTfh17 Cells | 50.9 ± 30.4 | 45.8 ± 27.8 | 43.7 ± 29.3 | 45.1 ± 31.4 |
| Week 54: CXCR4+ cTfh17 Cells | 56.1 ± 31.1 | 54.0 ± 29.3 | 53.1 ± 31.4 | 56.4 ± 29.6 |
| Week 80: CXCR4+ cTfh17 Cells | 60.0 ± 27.4 | 57.2 ± 30.3 | 54.6 ± 31.4 | 57.6 ± 28.5 |
| Week 0: CXCR4+ Ctfh2 Cells | 58.8 ± 26.8 | 56.3 ± 25.2 | 54.0 ± 26.3 | 54.5 ± 28.8 |
| Week 54: CXCR4+ Ctfh2 Cells | 63.3 ± 28.2 | 65.2 ± 27.3 | 63.7 ± 28.5 | 67.7 ± 25.3 |
| Week 80: CXCR4+ Ctfh2 Cells | 69.3 ± 23.9 | 65.8 ± 27.1 | 62.7 ± 29.5 | 66.7 ± 24.7 |
| Week 0: Circulating TFH-Cells (cTfh) | 5.5 ± 3.7 | 5.4 ± 3.4 | 6.2 ± 3.3 | 6.1 ± 3.7 |
| Week 54: Circulating TFH-Cells (cTfh) | 5.7 ± 3.3 | 5.6 ± 3.9 | 6.2 ± 4.0 | 6.2 ± 4.4 |
| Week 80: Circulating TFH-Cells (cTfh) | 5.8 ± 3.3 | 5.9 ± 4.1 | 6.1 ± 4.2 | 5.8 ± 3.8 |
| Week 0: ICOS+ CD4 CM | 0.5 ± 0.5 | 0.5 ± 0.5 | 0.4 ± 0.3 | 0.5 ± 0.4 |
| Week 54: ICOS+ CD4 CM | 0.3 ± 0.2 | 0.3 ± 0.2 | 0.4 ± 0.2 | 0.4 ± 0.3 |
| Week 80: ICOS+ CD4 CM | 0.3 ± 0.3 | 0.3 ± 0.2 | 0.3 ± 0.2 | 0.3 ± 0.2 |
| Week 0: ICOS+ CD4 EM | 0.2 ± 0.2 | 0.3 ± 0.6 | 0.2 ± 0.2 | 0.2 ± 0.2 |
| Week 54: ICOS+ CD4 EM | 0.2 ± 0.1 | 0.2 ± 0.1 | 0.2 ± 0.1 | 0.2 ± 0.1 |
| Week 80: ICOS+ CD4 EM | 0.2 ± 0.1 | 0.2 ± 0.1 | 0.2 ± 0.5 | 0.2 ± 0.1 |
| Week 0: ICOS+ CD4 TEMRA | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.0 |
| Week 54: ICOS+ CD4 TEMRA | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.0 |
| Week 80: ICOS+ CD4 TEMRA | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.1 | 0.0 ± 0.0 |
| Week 0: ICOS+ NAIVE CD4 T-Cells | 0.1 ± 0.1 | 0.1 ± 0.1 | 0.1 ± 0.1 | 0.1 ± 0.1 |
| Week 54: ICOS+ NAIVE CD4 T-Cells | 0.0 ± 0.1 | 0.0 ± 0.0 | 0.0 ± 0.1 | 0.1 ± 0.1 |
| Week 80: ICOS+ NAIVE CD4 T-Cells | 0.0 ± 0.1 | 0.0 ± 0.0 | 0.0 ± 0.1 | 0.0 ± 0.0 |
| Week 0: ICOS+ NAIVE TREG | 2.3 ± 1.8 | 2.7 ± 3.4 | 1.9 ± 2.1 | 2.5 ± 2.8 |
| Week 54: ICOS+ NAIVE TREG | 2.1 ± 2.0 | 2.0 ± 2.4 | 1.9 ± 2.5 | 2.4 ± 2.5 |
| Week 80: ICOS+ NAIVE TREG | 2.2 ± 2.2 | 2.1 ± 2.4 | 1.9 ± 2.3 | 2.7 ± 2.7 |
| Week 0: ICOS+ TREG CM | 10.9 ± 5.3 | 11.3 ± 5.8 | 10.4 ± 5.4 | 11.0 ± 5.9 |
| Week 54: ICOS+ TREG CM | 10.0 ± 5.2 | 9.2 ± 4.4 | 9.7 ± 4.7 | 10.6 ± 5.1 |
| Week 80: ICOS+ TREG CM | 10.1 ± 4.9 | 9.0 ± 4.3 | 8.8 ± 5.2 | 10.5 ± 4.4 |
| Week 0: ICOS+ TREG EM | 12.8 ± 6.4 | 13.3 ± 6.8 | 13.0 ± 6.2 | 12.8 ± 6.5 |
| Week 54: ICOS+ TREG EM | 11.9 ± 5.8 | 11.6 ± 5.9 | 12.8 ± 6.1 | 12.7 ± 5.9 |
| Week 80: ICOS+ TREG EM | 12.0 ± 5.5 | 11.3 ± 5.4 | 10.5 ± 5.3 | 12.0 ± 5.8 |
| Week 0: ICOS+ TREG TEMRA | 10.2 ± 10.6 | 13.0 ± 18.4 | 10.5 ± 11.4 | 9.3 ± 8.6 |
| Week 54: ICOS+ TREG TEMRA | 8.8 ± 10.5 | 9.7 ± 10.7 | 11.0 ± 12.6 | 12.8 ± 15.1 |
| Week 80: ICOS+ TREG TEMRA | 9.9 ± 9.8 | 9.6 ± 10.1 | 8.2 ± 9.2 | 11.0 ± 10.5 |
| Week 0: PD1+ CD4 Central Memory | 6.2 ± 4.0 | 6.7 ± 4.9 | 7.2 ± 5.3 | 6.6 ± 4.3 |
| Week 54: PD1+ CD4 Central Memory | 6.4 ± 4.7 | 6.8 ± 5.4 | 7.2 ± 5.4 | 6.7 ± 3.9 |
| Week 80: PD1+ CD4 Central Memory | 6.7 ± 5.5 | 7.5 ± 5.9 | 6.8 ± 4.8 | 7.2 ± 5.3 |
| Week 0: PD1+ CD4 Effector Memory | 4.0 ± 3.2 | 4.2 ± 2.3 | 4.0 ± 2.8 | 4.1 ± 2.6 |
| Week 54: PD1+ CD4 Effector Memory | 3.7 ± 3.0 | 3.9 ± 2.2 | 3.6 ± 2.3 | 4.0 ± 2.5 |
| Week 80: PD1+ CD4 Effector Memory | 3.9 ± 2.7 | 4.3 ± 2.3 | 3.6 ± 2.2 | 4.3 ± 2.4 |
| Week 0: PD1+ Naive CD4 | 3.8 ± 6.1 | 3.0 ± 4.7 | 4.2 ± 6.8 | 3.2 ± 4.4 |
| Week 54: PD1+ Naive CD4 | 4.2 ± 6.2 | 2.9 ± 4.0 | 4.4 ± 6.8 | 3.5 ± 4.6 |
| Week 80: PD1+ Naive CD4 | 5.0 ± 8.4 | 3.3 ± 4.6 | 4.2 ± 6.6 | 3.8 ± 6.2 |
| Week 0: PD1+ Naive TREG | 8.4 ± 6.8 | 8.7 ± 7.5 | 8.4 ± 7.9 | 8.5 ± 8.0 |
| Week 54: PD1+ Naive TREG | 9.8 ± 7.9 | 9.4 ± 9.5 | 9.1 ± 8.5 | 9.4 ± 8.2 |
| Week 80: PD1+ Naive TREG | 11.0 ± 9.8 | 10.1 ± 9.1 | 9.3 ± 8.2 | 10.7 ± 9.2 |
| Week 0: PD1+ TEMRA TREG | 22.5 ± 19.0 | 23.5 ± 17.5 | 19.8 ± 15.0 | 19.5 ± 13.5 |
| Week 54: PD1+ TEMRA TREG | 20.5 ± 13.7 | 19.7 ± 16.2 | 18.6 ± 14.0 | 21.4 ± 13.9 |
| Week 80: PD1+ TEMRA TREG | 22.5 ± 15.0 | 25.7 ± 19.5 | 22.4 ± 16.6 | 22.7 ± 13.0 |
| Week 0: PD1+ TREG CM | 16.8 ± 10.0 | 17.5 ± 11.5 | 17.3 ± 11.0 | 17.2 ± 10.2 |
| Week 54: PD1+ TREG CM | 16.5 ± 10.5 | 16.7 ± 10.9 | 16.8 ± 11.4 | 18.0 ± 10.6 |
| Week 80: PD1+ TREG CM | 18.1 ± 13.0 | 18.7 ± 11.2 | 16.6 ± 11.0 | 18.8 ± 11.6 |
| Week 0: PD1+ TREG EM | 20.1 ± 9.9 | 21.1 ± 11.4 | 21.6 ± 10.9 | 20.9 ± 10.0 |
| Week 54: PD1+ TREG EM | 19.3 ± 10.5 | 19.8 ± 10.3 | 21.1 ± 11.6 | 21.6 ± 10.7 |
| Week 80: PD1+ TREG EM | 20.6 ± 12.2 | 21.1 ± 10.5 | 19.4 ± 10.6 | 21.9 ± 10.0 |
| Week 0: PD1+ICOSNeg cTfh1 | 30.0 ± 14.8 | 28.8 ± 15.3 | 32.4 ± 16.5 | 29.7 ± 13.2 |
| Week 54: PD1+ICOSNeg cTfh1 | 30.5 ± 16.2 | 29.1 ± 13.9 | 34.2 ± 19.0 | 31.0 ± 13.5 |
| Week 80: PD1+ICOSNeg cTfh1 | 32.4 ± 18.1 | 30.7 ± 16.0 | 31.3 ± 14.0 | 32.8 ± 13.6 |
| Week 0: PD1+ICOSNeg cTfh17 | 21.8 ± 16.3 | 22.5 ± 16.3 | 23.7 ± 17.1 | 22.3 ± 15.7 |
| Week 54: PD1+ICOSNeg cTfh17 | 21.8 ± 17.4 | 21.1 ± 16.9 | 26.2 ± 19.7 | 21.7 ± 15.5 |
| Week 80: PD1+ICOSNeg cTfh17 | 26.8 ± 19.2 | 24.7 ± 16.0 | 23.6 ± 15.8 | 24.3 ± 15.5 |
| Week 0: PD1+ICOSNeg cTfh2 | 19.1 ± 12.0 | 18.4 ± 12.6 | 20.8 ± 14.3 | 18.5 ± 11.2 |
| Week 54: PD1+ICOSNeg cTfh2 | 18.4 ± 13.3 | 18.1 ± 13.1 | 20.2 ± 14.4 | 18.8 ± 11.7 |
| Week 80: PD1+ICOSNeg cTfh2 | 20.2 ± 16.6 | 19.6 ± 13.9 | 18.9 ± 11.7 | 20.2 ± 13.2 |
| Week 0: PD1- ICOS- cTfh1 | 68.4 ± 15.1 | 69.0 ± 16.3 | 64.6 ± 17.9 | 68.9 ± 13.5 |
| Week 54: PD1- ICOS- cTfh1 | 68.6 ± 16.4 | 68.0 ± 16.5 | 64.1 ± 19.7 | 67.5 ± 14.1 |
| Week 80: PD1- ICOS- cTfh1 | 66.7 ± 18.2 | 68.1 ± 16.1 | 67.4 ± 14.4 | 65.9 ± 14.0 |
| Week 0: PD1- ICOS- cTfh17 | 75.6 ± 18.8 | 74.7 ± 18.2 | 73.4 ± 19.3 | 75.3 ± 18.1 |
| Week 54: PD1- ICOS- cTfh17 | 77.4 ± 17.9 | 72.9 ± 23.7 | 70.9 ± 21.5 | 73.5 ± 20.9 |
| Week 80: PD1- ICOS- cTfh17 | 72.1 ± 20.1 | 74.0 ± 16.2 | 73.6 ± 18.7 | 74.6 ± 15.8 |
| Week 0: PD1- ICOS- cTfh2 | 80.1 ± 12.2 | 80.8 ± 12.8 | 78.3 ± 14.2 | 80.7 ± 11.5 |
| Week 54: PD1- ICOS- cTfh2 | 81.0 ± 13.3 | 81.3 ± 13.3 | 78.8 ± 14.3 | 80.3 ± 11.9 |
| Week 80: PD1- ICOS- cTfh2 | 79.1 ± 16.9 | 79.8 ± 13.9 | 80.4 ± 11.9 | 79.0 ± 13.4 |
| Week 0: Potentially Anergic TEMRA CD4 | 0.7 ± 2.5 | 0.2 ± 0.3 | 0.4 ± 1.0 | 0.3 ± 0.7 |
| Week 54: Potentially Anergic TEMRA CD4 | 0.8 ± 3.0 | 0.2 ± 0.3 | 0.5 ± 1.3 | 0.3 ± 0.5 |
| Week 80: Potentially Anergic TEMRA CD4 | 0.8 ± 2.9 | 0.2 ± 0.3 | 0.5 ± 1.4 | 0.3 ± 0.7 |
| Week 0: Regulatory T-Follicular Subset | 0.2 ± 0.2 | 0.2 ± 0.2 | 0.2 ± 0.2 | 0.2 ± 0.2 |
| Week 54: Regulatory T-Follicular Subset | 0.2 ± 0.2 | 0.2 ± 0.2 | 0.2 ± 0.2 | 0.3 ± 0.2 |
| Week 80: Regulatory T-Follicular Subset | 0.2 ± 0.2 | 0.2 ± 0.3 | 0.2 ± 0.3 | 0.3 ± 0.3 |
| Week 0: TH17-Like Circulating T-Follicular cells | 0.5 ± 0.5 | 0.4 ± 0.4 | 0.5 ± 0.5 | 0.5 ± 0.5 |
| Week 54: TH17-Like Circulating T-Follicular cells | 0.4 ± 0.4 | 0.4 ± 0.4 | 0.4 ± 0.5 | 0.4 ± 0.4 |
| Week 80: TH17-Like Circulating T-Follicular cells | 0.4 ± 0.5 | 0.4 ± 0.5 | 0.3 ± 0.3 | 0.4 ± 0.5 |
| Week 0: TH2-Like Circulating T-Follicular Cells | 3.6 ± 2.2 | 3.6 ± 2.0 | 4.0 ± 2.0 | 4.1 ± 2.3 |
| Week 54: TH2-Like Circulating T-Follicular Cells | 3.9 ± 2.0 | 3.6 ± 2.2 | 4.0 ± 2.3 | 3.9 ± 2.5 |
| Week 80: TH2-Like Circulating T-Follicular Cells | 3.8 ± 2.0 | 3.7 ± 2.1 | 3.9 ± 2.2 | 3.8 ± 2.1 |
| Week 0: TIGIT+ cTfh1 | 53.0 ± 11.6 | 48.5 ± 13.9 | 53.4 ± 12.4 | 51.6 ± 13.1 |
| Week 54: TIGIT+ cTfh1 | 51.1 ± 13.1 | 47.6 ± 13.9 | 52.2 ± 14.1 | 50.2 ± 14.1 |
| Week 80: TIGIT+ cTfh1 | 51.4 ± 11.1 | 48.1 ± 14.4 | 49.6 ± 10.4 | 52.7 ± 12.2 |
| Week 0: TIGIT+ cTfh17 | 40.5 ± 16.2 | 36.2 ± 13.1 | 39.3 ± 14.5 | 38.7 ± 14.9 |
| Week 54: TIGIT+ cTfh17 | 37.0 ± 13.5 | 31.4 ± 16.5 | 40.7 ± 14.7 | 35.8 ± 15.6 |
| Week 80: TIGIT+ cTfh17 | 39.4 ± 14.5 | 35.9 ± 13.9 | 35.3 ± 12.7 | 36.8 ± 13.8 |
| Week 0: TIGIT+ cTfh2 | 44.4 ± 9.5 | 40.9 ± 9.8 | 44.8 ± 7.4 | 43.4 ± 9.8 |
| Week 54: TIGIT+ cTfh2 | 41.1 ± 11.0 | 37.9 ± 10.9 | 42.0 ± 9.6 | 41.0 ± 11.6 |
| Week 80: TIGIT+ cTfh2 | 40.7 ± 10.4 | 38.4 ± 9.5 | 40.5 ± 8.4 | 41.9 ± 9.9 |
| Week 0: TOTAL ICOS+ TREG | 8.6 ± 4.4 | 9.6 ± 5.5 | 8.0 ± 3.8 | 8.9 ± 4.5 |
| Week 54: TOTAL ICOS+ TREG | 8.3 ± 4.8 | 7.5 ± 3.5 | 7.6 ± 3.8 | 8.6 ± 3.6 |
| Week 80: TOTAL ICOS+ TREG | 8.3 ± 4.4 | 7.4 ± 3.6 | 6.6 ± 3.3 | 8.6 ± 3.6 |
| Week 0: Th1-Like Circulating T-Follicular Cells | 1.3 ± 1.4 | 1.3 ± 1.2 | 1.6 ± 1.2 | 1.5 ± 1.3 |
| Week 54: Th1-Like Circulating T-Follicular Cells | 1.4 ± 1.2 | 1.6 ± 1.7 | 1.8 ± 1.5 | 1.8 ± 1.9 |
| Week 80: Th1-Like Circulating T-Follicular Cells | 1.5 ± 1.4 | 1.8 ± 1.9 | 1.9 ± 2.0 | 1.6 ± 1.5 |
| Week 0: Total PD1+ TREG | 14.5 ± 7.9 | 15.1 ± 8.2 | 14.7 ± 8.9 | 14.4 ± 7.4 |
| Week 54: Total PD1+ TREG | 14.8 ± 9.1 | 14.3 ± 8.5 | 14.5 ± 9.1 | 15.0 ± 7.6 |
| Week 80: Total PD1+ TREG | 16.0 ± 10.6 | 15.9 ± 8.3 | 14.2 ± 9.0 | 16.1 ± 8.9 |
Myeloid panel is evaluated by Immune phenotyping of peripheral blood mononuclear cells (PBMC) at baseline (week 0), week 54 and week 80. In below table HLA refers to Human Leukocyte Antigen; MDSC refers to myeloid-derived suppressor cell; DC refers to Dendritic cells; MYDC refers to Myeloid Dendritic Cells; IMMYE_MDSC refers to Immature myeloid cells \& a subset of myeloid suppressor cells within the CD14-HLA class II- myeloid cell population.
| Percentage of Myeloid cells (%) | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Week 0: CD14+ HLA low Myeloid Cells | 1.1 ± 1.5 | 1.0 ± 1.3 | 0.9 ± 1.2 | 1.0 ± 1.4 |
| Week 54: CD14+ HLA low Myeloid Cells | 1.1 ± 2.3 | 0.7 ± 0.9 | 0.7 ± 1.1 | 0.6 ± 1.1 |
| Week 80: CD14+ HLA low Myeloid Cells | 1.0 ± 2.2 | 0.6 ± 0.7 | 0.9 ± 1.2 | 0.8 ± 1.1 |
| Week 0: CD14+ MDSC | 68.2 ± 20.8 | 69.1 ± 22.3 | 73.5 ± 19.4 | 70.3 ± 18.6 |
| Week 54: CD14+ MDSC | 64.0 ± 23.4 | 67.0 ± 23.2 | 69.3 ± 21.4 | 65.9 ± 20.2 |
| Week 80: CD14+ MDSC | 65.7 ± 22.3 | 62.7 ± 20.8 | 64.1 ± 23.3 | 63.9 ± 23.2 |
| Week 0: CD14-HLA II- Myeloid Cells Total Myeloid | 80.4 ± 11.0 | 82.2 ± 10.4 | 80.8 ± 12.1 | 81.8 ± 11.0 |
| Week 54: CD14-HLA II- Myeloid Cells Total Myeloid | 80.9 ± 11.7 | 80.0 ± 12.0 | 80.8 ± 12.7 | 83.5 ± 10.5 |
| Week 80: CD14-HLA II- Myeloid Cells Total Myeloid | 79.0 ± 12.9 | 81.0 ± 10.8 | 80.9 ± 9.7 | 81.3 ± 8.4 |
| Week 0: CD16+ Dendritic Cells | 12.5 ± 8.4 | 11.3 ± 7.5 | 12.9 ± 10.6 | 11.5 ± 7.5 |
| Week 54: CD16+ Dendritic Cells | 10.2 ± 8.1 | 10.3 ± 7.5 | 11.2 ± 9.7 | 12.0 ± 9.7 |
| Week 80: CD16+ Dendritic Cells | 11.7 ± 10.6 | 9.4 ± 6.1 | 9.2 ± 7.1 | 12.1 ± 8.0 |
| Week 0: IMMYE_MDSC | 0.3 ± 0.2 | 0.2 ± 0.2 | 0.2 ± 0.2 | 0.2 ± 0.4 |
| Week 54: IMMYE_MDSC | 0.2 ± 0.3 | 0.2 ± 0.3 | 0.2 ± 0.3 | 0.1 ± 0.2 |
| Week 80: IMMYE_MDSC | 0.2 ± 0.3 | 0.1 ± 0.2 | 0.2 ± 0.2 | 0.2 ± 0.2 |
| Week 0: Intermediate Monocyte Subset | 8.6 ± 8.4 | 9.0 ± 7.8 | 8.3 ± 8.8 | 7.7 ± 7.3 |
| Week 54: Intermediate Monocyte Subset | 6.5 ± 4.8 | 7.3 ± 6.7 | 6.3 ± 7.1 | 5.8 ± 5.4 |
| Week 80: Intermediate Monocyte Subset | 6.0 ± 5.1 | 6.6 ± 6.5 | 5.7 ± 5.4 | 5.8 ± 4.5 |
| Week 0: Non-Classical Monocytes | 1.5 ± 1.3 | 1.3 ± 0.8 | 1.2 ± 0.8 | 1.3 ± 1.0 |
| Week 54: Non-Classical Monocytes | 1.2 ± 1.1 | 1.3 ± 0.8 | 1.1 ± 0.8 | 1.2 ± 0.9 |
| Week 80: Non-Classical Monocytes | 1.2 ± 0.7 | 1.2 ± 0.7 | 1.0 ± 0.6 | 1.3 ± 0.9 |
| Week 0: Total Classical Monocytes | 87.2 ± 9.3 | 86.7 ± 8.1 | 87.6 ± 9.1 | 88.0 ± 8.0 |
| Week 54: Total Classical Monocytes | 87.8 ± 7.9 | 88.1 ± 7.6 | 88.0 ± 8.8 | 89.3 ± 6.8 |
| Week 80: Total Classical Monocytes | 89.3 ± 6.0 | 88.5 ± 7.1 | 88.6 ± 7.0 | 89.7 ± 5.4 |
| Week 0: Total Monocytes in Myeloid Cells | 14.2 ± 8.9 | 12.6 ± 7.8 | 14.1 ± 9.5 | 13.4 ± 8.7 |
| Week 54: Total Monocytes in Myeloid Cells | 13.8 ± 9.3 | 14.9 ± 9.8 | 14.3 ± 10.6 | 12.2 ± 8.3 |
| Week 80: Total Monocytes in Myeloid Cells | 15.5 ± 10.3 | 13.8 ± 9.1 | 13.6 ± 7.6 | 13.5 ± 6.3 |
| Week 0: Total Myeloid DC | 3.8 ± 2.1 | 3.6 ± 2.3 | 3.8 ± 2.8 | 3.4 ± 2.0 |
| Week 54: Total Myeloid DC | 3.7 ± 2.3 | 3.9 ± 2.4 | 3.8 ± 2.4 | 3.2 ± 2.1 |
| Week 80: Total Myeloid DC | 4.1 ± 2.3 | 4.1 ± 2.5 | 4.1 ± 3.0 | 3.9 ± 2.1 |
| Week 0: Total MYDC | 30.4 ± 9.1 | 31.4 ± 10.2 | 32.7 ± 9.2 | 31.0 ± 9.6 |
| Week 54: Total MYDC | 30.4 ± 11.3 | 31.3 ± 8.5 | 31.7 ± 11.9 | 27.2 ± 9.2 |
| Week 80: Total MYDC | 28.7 ± 10.7 | 30.5 ± 7.9 | 31.6 ± 12.0 | 31.9 ± 10.2 |
| Week 0: Total Percent Of Myeloid Cells | 94.6 ± 3.8 | 94.7 ± 5.4 | 94.6 ± 3.4 | 94.6 ± 4.1 |
| Week 54: Total Percent Of Myeloid Cells | 95.1 ± 3.6 | 95.9 ± 4.0 | 95.0 ± 3.8 | 95.6 ± 3.7 |
| Week 80: Total Percent Of Myeloid Cells | 94.8 ± 5.4 | 95.6 ± 4.0 | 94.6 ± 4.4 | 94.1 ± 5.1 |
| Week 0: Total Plasmacytoid Dendritic Cells (PDC) | 14.3 ± 5.4 | 12.5 ± 6.6 | 12.0 ± 6.3 | 12.9 ± 7.5 |
| Week 54: Total Plasmacytoid Dendritic Cells (PDC) | 14.4 ± 6.7 | 13.5 ± 5.9 | 12.0 ± 6.1 | 11.8 ± 6.5 |
| Week 80: Total Plasmacytoid Dendritic Cells (PDC) | 13.5 ± 6.6 | 12.8 ± 6.7 | 11.6 ± 6.3 | 12.5 ± 6.7 |
Participants were analyzed for autoantibodies against Glutamic acid decarboxylase (GAD) and were categorized as negative and positive.
| Participants | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Week 0 — Negative | 3 | 1 | 5 | 3 |
| Week 0 — Positive | 74 | 76 | 71 | 74 |
| Week 54 — Negative | 5 | 4 | 4 | 3 |
| Week 54 — Positive | 62 | 61 | 64 | 63 |
| Week 80 — Negative | 4 | 2 | 5 | 1 |
| Week 80 — Positive | 61 | 62 | 63 | 61 |
Participants were analyzed for autoantibodies against Zinc-transporter 8 (ZnT8) and were categorized as negative and positive.
| Participants | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Week 0 — Negative | 29 | 30 | 30 | 36 |
| Week 0 — Positive | 48 | 47 | 46 | 41 |
| Week 54 — Negative | 26 | 28 | 27 | 33 |
| Week 54 — Positive | 42 | 37 | 41 | 33 |
| Week 80 — Negative | 23 | 30 | 31 | 33 |
| Week 80 — Positive | 42 | 34 | 37 | 29 |
Participants were analyzed for autoantibodies against Islet antigen-2 (IA2) and were categorized as negative and positive.
| Participants | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Week 0 — Negative | 38 | 37 | 31 | 45 |
| Week 0 — Positive | 39 | 40 | 45 | 32 |
| Week 54 — Negative | 35 | 33 | 28 | 38 |
| Week 54 — Positive | 33 | 32 | 40 | 28 |
| Week 80 — Negative | 32 | 38 | 29 | 35 |
| Week 80 — Positive | 33 | 26 | 39 | 27 |
Participants were analyzed for autoantibodies against Insulin autoantibodies (IAA) and were categorized as negative and positive.
| Participants | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Week 0 — Negative | 35 | 28 | 26 | 36 |
| Week 0 — Positive | 42 | 48 | 49 | 40 |
| Week 54 — Negative | 30 | 28 | 22 | 11 |
| Week 54 — Positive | 38 | 37 | 46 | 55 |
| Week 80 — Negative | 18 | 24 | 13 | 15 |
| Week 80 — Positive | 48 | 40 | 55 | 47 |
IL-21 is evaluated at baseline (week 0), week 54 and week 80.
| picogram per milliliter | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Week 0 | 28.8 ± 10.2 | 31.1 ± 10.8 | 30.9 ± 10.7 | 30.2 ± 10.2 |
| Week 54 | 3993.5 ± 2145.4 | 4368.2 ± 2374.9 | 25.0 ± 0.0 | 34.1 ± 68.1 |
| Week 80 | 540.9 ± 495.3 | 674.1 ± 648.1 | 28.0 ± 8.2 | 30.7 ± 17.2 |
Serum vitamin D is evaluated at baseline (week 0), week 54 and week 80.
| picomole per liter | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Week 0 | 123 ± 30 | 122 ± 39 | 122 ± 29 | 120 ± 33 |
| Week 54 | 117 ± 31 | 125 ± 36 | 113 ± 30 | 119 ± 32 |
| Week 80 | 119 ± 41 | 124 ± 49 | 121 ± 38 | 115 ± 33 |
SF-36v2™ questionnaire measured the HRQoL on 8 domains (Bodily Pain, General Health, Mental Health, Physical Functioning, Role Emotion, Physical Health, Social Functioning and Vitality) on individual scale ranges. The scores 0-100 (where higher scores indicated a better HRQoL) from the SF-36 were converted to norm-based scores to enable a direct interpretation in relation to the distribution of the scores in the 2009 U.S. general population. Change from baseline (week 0) to week 54 and week 80 in SF-36 score is presented.The MCS measure is derived from domain scales of vitality, social functioning, role emotional and mental health. The PCS measure is derived from domain scales of physical functioning, role-physical, bodily pain, and general health. A norm-based score of 50 corresponds to the mean score and 10 corresponds to the standard deviation of the 2009 U.S. general population. A positive change score indicate an improvement since baseline.
| Score on a scale | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Week 54: Bodily pain | -0.8 ± 8.5 | -2.2 ± 7.6 | 0.1 ± 5.2 | 0.6 ± 9.1 |
| Week 80: Bodily Pain | 0.8 ± 7.8 | -1.4 ± 7.0 | -0.5 ± 6.4 | 0.8 ± 10.2 |
| Week 54: General Health Perception | -1.1 ± 7.1 | -0.3 ± 8.4 | -1.6 ± 7.3 | -1.0 ± 7.1 |
| Week 80: General Health Perception | -0.9 ± 7.2 | 0.6 ± 9.0 | -1.7 ± 7.9 | -1.8 ± 8.6 |
| Week 54: Mental Component Sum | 0.5 ± 9.4 | 0.6 ± 9.3 | -2.1 ± 9.0 | -1.3 ± 7.6 |
| Week 80: Mental Component Sum | 1.7 ± 9.8 | -0.4 ± 8.9 | -2.4 ± 9.6 | -0.7 ± 8.7 |
| week 54: Mental Health | 0.7 ± 8.4 | 0.6 ± 7.9 | -1.5 ± 8.6 | -1.3 ± 6.9 |
| Week 80: Mental Health | 1.5 ± 8.6 | -0.2 ± 8.0 | -1.5 ± 9.0 | -0.7 ± 7.6 |
| Week 54: Physical Component Sum | -0.4 ± 4.2 | -0.4 ± 5.3 | -0.1 ± 3.8 | 0.3 ± 5.7 |
| Week 80: Physical Component Sum | -0.1 ± 3.9 | 0.5 ± 5.4 | 0.0 ± 4.3 | 0.0 ± 6.9 |
| Week 54: Physical Functioning | 0.6 ± 2.5 | 0.9 ± 4.4 | 0.0 ± 2.6 | 0.3 ± 5.8 |
| Week 80: Physical Functioning | 0.5 ± 2.9 | 1.1 ± 4.6 | -0.1 ± 2.4 | 0.1 ± 6.4 |
| Week 54:Lim Emotion Prob | 0.3 ± 10.7 | 0.5 ± 8.9 | -1.4 ± 9.0 | -0.1 ± 8.5 |
| Week 80: Lim Emotion Prob | 1.2 ± 10.8 | -0.1 ± 9.8 | -2.2 ± 9.4 | 0.0 ± 8.3 |
| Week 54: Lim. Phy Health | 0.3 ± 5.8 | 0.7 ± 6.9 | -0.6 ± 5.7 | -0.2 ± 6.9 |
| Week 80: Lim. Phy Health | 0.8 ± 6.4 | 0.9 ± 7.0 | -0.2 ± 5.2 | 0.0 ± 7.3 |
| Week 54: Social Functioning | 0.8 ± 10.3 | 0.1 ± 10.0 | -1.4 ± 7.4 | 0.0 ± 8.5 |
| Week 80: Social Functioning | 2.3 ± 9.9 | 1.0 ± 8.3 | -1.2 ± 7.3 | -0.4 ± 8.4 |
| Week 54: Vitality | -0.5 ± 8.2 | 0.5 ± 7.9 | -2.2 ± 5.9 | -2.3 ± 6.9 |
| Week 80: Vitality | 0.5 ± 7.9 | -1.4 ± 6.9 | -2.2 ± 7.1 | -0.7 ± 6.9 |
Treatment Benefits and Barriers (ETBB) questionnaire measured diabetes-specific health beliefs on 2 categories: Total Score for Perceived Barriers and Perceived Benefits. The measurement of perceived benefits of, and barriers to, treatment was achieved by creating a pool 28 statements each with a 7-point scale ranging from strongly agree (6) to strongly disagree (0). ETBB benefits score was calculated using the responses from questions 1, 4, 7, 8, 10, and 12 and ETBB barriers score was calculated using the responses from questions 2, 3, 5, 6, 9, and 11. Both was calculated as the sum of responses divided by number of responses received multiplied by the maximum number of responses. Based on the responses used the maximum responses available was 6. The higher score indicates more perceived benefits or more perceived barrier.
| score on a scale | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Week 54: Total Score for Perceived Barriers | -1.2 ± 8.3 | -1.8 ± 7.7 | -0.2 ± 8.2 | -0.3 ± 6.3 |
| Week 80: Total Score for Perceived Barriers | -2.0 ± 7.8 | -2.0 ± 7.5 | -0.1 ± 6.7 | 0.1 ± 8.3 |
| Week 54: Total Score for Perceived Benefits | 0.6 ± 5.6 | 1.1 ± 4.2 | 0.2 ± 5.7 | -0.5 ± 6.3 |
| Week 80: Total Score for Perceived Benefits | 0.1 ± 5.8 | 1.1 ± 4.8 | 1.3 ± 6.2 | -0.4 ± 5.1 |
Change from baseline (week 0) in DTSQ is evaluated at week 54 and 80. The DTSQs items are scored on a 7-point graded response scale ranging from 6 to 0. Higher score indicates a higher level of glycaemia/treatment satisfaction.
| Score on a scale | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Week 54: Perceived frequency of hyperglycaemia | 0.6 ± 1.9 | 0.0 ± 1.5 | 0.0 ± 1.9 | 0.5 ± 1.7 |
| Week 80: Perceived frequency of hyperglycaemia | 0.9 ± 1.8 | 0.5 ± 1.8 | 0.6 ± 2.0 | 0.7 ± 1.9 |
| Week 54: Perceived frequency of hypoglycaemia | -0.7 ± 2.1 | -0.6 ± 1.6 | -0.4 ± 2.1 | -0.2 ± 1.5 |
| Week 80: Perceived frequency of hypoglycaemia | -0.9 ± 1.8 | -0.3 ± 1.7 | -0.4 ± 1.8 | -0.1 ± 1.5 |
| Week 54: Treatment satisfaction | 1.5 ± 4.8 | 0.9 ± 5.2 | 1.3 ± 4.8 | 0.2 ± 5.5 |
| Week 80: Treatment satisfaction | 1.3 ± 6.1 | 1.2 ± 5.7 | 0.0 ± 5.1 | 0.2 ± 6.2 |
Area under the concentration-time curve, from 0 to 4 hours (AUC0-4h) of a mixed meal tolerance test (MMTT) stimulated C-peptide at week 80 is presented as ratio to baseline. AUC of C-peptide was measured as Nano moles\*hour per liter (nmol\*h/L).
| Ratio of AUC | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Area Under the Concentration-time Curve (AUC) 0-4h of Mixed Meal Tolerance Test (MMTT) Stimulated C-peptide at Week 80 Relative to Baseline | 0.566 ± 71.3 | 0.598 ± 70.2 | 0.373 ± 115.8 | 0.571 ± 100.9 |
Area under the concentration-time curve, from 0 to 2 hours (AUC0-2h) of a MMTT stimulated C-peptide at week 80 is presented as ratio to baseline. AUC of C-peptide was measured as 'nmol\*h/L'.
| Ratio of AUC | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| AUC0-2h of C-peptide at Week 80 Relative to Baseline | 0.590 ± 74.5 | 0.619 ± 71.2 | 0.370 ± 111.5 | 0.540 ± 120.6 |
Maximum observed concentration (Cmax) of a MMTT stimulated C-peptide at week 80 is presented as ratio to baseline. Cmax of C-peptide was measured as nanomoles per liter (nmol/L).
| Ratio of Cmax | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Cmax of C-peptide at Week 80 Relative to Baseline | 0.580 ± 74.8 | 0.592 ± 76.8 | 0.389 ± 109.0 | 0.568 ± 97.7 |
Area under the concentration-time curve, from 0 to 4 hours (AUC0-4h) of a MMTT stimulated glucose at week 80 is presented as ratio to baseline. AUC of glucose was measured as Milli moles\*hour per liter (mmol\*h/L).
| Ratio of AUC | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| AUC0-4h of Glucose at Week 80 Relative to Baseline | 1.129 ± 33.3 | 1.115 ± 32.6 | 1.136 ± 39.0 | 1.221 ± 26.6 |
Area under the concentration-time curve, from 0 to 2 hours (AUC0-2h) of a MMTT stimulated glucose at week 80 is presented as ratio to baseline. AUC of glucose was measured as 'mmol\*h/L'.
| Ratio of AUC | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| AUC0-2h of Glucose at Week 80 Relative to Baseline | 1.119 ± 28.6 | 1.086 ± 28.1 | 1.070 ± 35.5 | 1.166 ± 21.7 |
Maximum observed concentration (Cmax) of a MMTT stimulated glucose at week 80 is presented as ratio to baseline. Cmax of C-peptide was measured as 'mmol/L'.
| Ratio of Cmax | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) |
|---|---|---|---|---|
| Cmax of Glucose at Week 80 Relative to Baseline | 1.114 ± 25.6 | 1.074 ± 28.7 | 1.104 ± 31.0 | 1.155 ± 21.5 |
Collected over Weeks 0-80. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| NNC0114-0006 + Liraglutide | 0/77 (0%) | 7/77 (9.1%) | 57/77 (74%) |
| NNC0114-0006 | 0/77 (0%) | 5/77 (6.5%) | 55/77 (71.4%) |
| Liraglutide | 1/76 (1.3%) | 9/76 (11.8%) | 62/76 (81.6%) |
| Placebo | 0/77 (0%) | 11/77 (14.3%) | 54/77 (70.1%) |
| Event | NNC0114-0006 + Liraglutide | NNC0114-0006 | Liraglutide | Placebo |
|---|---|---|---|---|
| Diabetic metabolic decompensationMetabolism and nutrition disorders | 2/77 | 0/77 | 1/76 | 2/77 |
| Brain oedemaNervous system disorders | 0/77 | 0/77 | 1/76 | 0/77 |
| Clavicle fractureInjury, poisoning and procedural complications | 0/77 | 0/77 | 1/76 | 0/77 |
| ConcussionInjury, poisoning and procedural complications | 0/77 | 0/77 | 1/76 | 1/77 |
| Diabetic ketoacidosisMetabolism and nutrition disorders | 0/77 | 0/77 | 1/76 | 1/77 |
| Genital herpes simplexInfections and infestations | 0/77 | 0/77 | 1/76 | 0/77 |
| Hypoglycaemic comaNervous system disorders | 0/77 | 0/77 | 1/76 | 0/77 |
| KetosisMetabolism and nutrition disorders | 0/77 | 0/77 | 1/76 | 0/77 |
| Nasal septum deviationRespiratory, thoracic and mediastinal disorders | 0/77 | 0/77 | 1/76 | 0/77 |
| Oral herpesInfections and infestations | 0/77 | 0/77 | 1/76 | 0/77 |
| Event | NNC0114-0006 + Liraglutide | NNC0114-0006 | Liraglutide | Placebo |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 19/77 | 6/77 | 42/76 | 9/77 |
| NasopharyngitisInfections and infestations | 20/77 | 27/77 | 25/76 | 25/77 |
| VomitingGastrointestinal disorders | 14/77 | 0/77 | 17/76 | 4/77 |
| DiarrhoeaGastrointestinal disorders | 15/77 | 9/77 | 13/76 | 9/77 |
| Decreased appetiteMetabolism and nutrition disorders | 14/77 | 2/77 | 11/76 | 1/77 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 10/77 | 13/77 | 5/76 | 9/77 |
| InfluenzaInfections and infestations | 6/77 | 12/77 | 2/76 | 2/77 |
| HeadacheNervous system disorders | 11/77 | 10/77 | 10/76 | 11/77 |
| Abdominal painGastrointestinal disorders | 9/77 | 0/77 | 4/76 | 7/77 |
| Upper respiratory tract infectionInfections and infestations | 8/77 | 5/77 | 4/76 | 7/77 |
The Full analysis set (FAS) included all randomised participants.
| Age, Continuous(years) | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) | Total |
|---|---|---|---|---|---|
| Mean | 28.0 ± 7.5 | 28.6 ± 7.9 | 28.0 ± 7.1 | 29.0 ± 7.0 | 28.4 ± 7.3 |
| Sex: Female, Male(Participants) | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) | Total |
|---|---|---|---|---|---|
| Female | 21 | 32 | 25 | 28 | 106 |
| Male | 56 | 45 | 51 | 49 | 201 |
| Ethnicity (NIH/OMB)(Participants) | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 4 | 3 | 2 | 1 | 10 |
| Not Hispanic or Latino | 73 | 74 | 74 | 76 | 297 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | NNC0114-0006 + Liraglutide (Experimental) | NNC0114-0006 (Experimental) | Liraglutide (Experimental) | Placebo (Placebo) | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 1 | 0 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 2 | 1 | 1 | 4 |
| White | 73 | 70 | 73 | 76 | 292 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 4 | 4 | 2 | 0 | 10 |
Showing the first 100 of 108 sites across 18 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2015 to primary completion in Aug 2018, 33 months.
Results were first posted in Jan 2021, 2 years 4 months after primary completion. A results delay was requested in Aug 2019.
Of 50 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 33. This study's 33 months is above that.
Counting every sponsor, half of 133 studies reached it within 36 months; a quarter within 17 and three quarters within 63.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: NNC0114-0006 · Liraglutide